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Abstract 
Integrins have the ability to impact major aspects of epithelial biology 
including adhesion, migration, invasion, signaling and differentiation, as well as 
the formation and progression of cancer (Hynes 2002; Srichai and Zent 2010; 
Anderson et al. 2014). This thesis focuses on how integrins are regulated and 
function in the context of mammary epithelial biology and breast cancer with a 
specific focus on the α6 integrin heterodimers (α6β1 and α6β4). These integrins 
function primarily as receptors for the laminin family of extracellular matrix (ECM) 
proteins and they have been implicated in mammary gland biology and breast 
cancer (Friedrichs et al. 1995; Wewer et al. 1997; Mercurio et al. 2001; 
Margadant and Sonnenberg 2010; Muschler and Streuli 2010; Nistico et al. 2014).   
The first project investigates how alternative splicing of the α6 subunit 
impacts the genesis and function of breast cancer stem cells (CSCs).  This work 
revealed that the α6Bβ1 splice variant, but not α6Aβ1, is necessary for the 
function of breast CSCs because it activates the Hippo transducer TAZ (Zhao et 
al. 2008a), which is known to be essential for breast CSCs (Cordenonsi et al. 
2011). My work also led to the discovery that laminin (LM) 511 is the specific 
ligand for α6Bβ1 and that autocrine LM511, which is mediated by TAZ, is needed 
to sustain breast CSCs by functioning as a ‘ECM niche’. An important aspect of 
this study is the finding that surface-bound LM511 characterizes a small 
population of cells in human breast tumors with CSC properties.  
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The second project of my thesis concentrated on identifying transcription 
factors that regulate expression of the β4 subunit. The expression of the α6β4 
integrin is repressed during the epithelial-mesenchymal transition (EMT) (Yang et 
al. 2009) but the contribution of specific transcription factors to this repression is 
poorly understood. This study revealed that Snai1 is a transcriptional repressor of 
β4, which is responsible for establishing the PRC2 (Polycomb complex 2)-
associated repressive histone mark H3K27Me3. However, I also found that the 
ability of Snai1 to repress transcription is abrogated by its interaction with Id2. 
Specifically, I identified the biochemical mechanism for how Id2 regulates Snai1. 
Id2 binds the SNAG domain of Snai1 that is the docking site for several co-
repressors (Peinado et al. 2004; Lin et al. 2010b; Dong et al. 2012a).  One 
important consequence of Id2 interacting with Snai1 on the β4 promoter is that it 
prevents repressive epigenetic modifications. This finding may explain why some 
epithelial cells express Snai1 and β4 because they also express Id2 (Vincent et 
al. 2009; Bastea et al. 2012). The repression of the α6β4 integrin during the EMT 
is consistent with data indicating that this integrin is not expressed in CSCs (Mani 
et al. 2008; Goel et al. 2012; Goel et al. 2013; Goel et al. 2014). An important 
question going forward is to understand how the α6β4 integrin contributes to 
tumor formation. 
In summary, my thesis provides novel insights into the biology of the α6 
integrins that has important implications for the function of these integrins in 
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mammary gland biology and breast cancer, especially our understanding of 
breast CSCs.  
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Chapter I  
Introduction 
Overview 
This thesis focuses on how specific integrins are regulated and function in the 
context of mammary epithelial biology and breast cancer. This issue is significant 
because integrins have the ability to impact major aspects of epithelial biology 
including adhesion, migration, invasion, signaling and differentiation, as well as 
the formation and progression of cancer (Hynes 2002; Lipscomb and Mercurio 
2005; Levental et al. 2009; Lathia et al. 2010; Margadant and Sonnenberg 2010; 
Srichai and Zent 2010). 
 
Mammary Epithelial Biology 
The mammary gland is composed of tree-like branching epithelial structures 
embedded in the mammary fat pad (Watson and Khaled 2008; Muschler and 
Streuli 2010), which serves as the stroma that provides essential physical 
support to the epithelial cells and contains extraceullar matrix (ECM), growth 
factors, and other cell types including adipose cells, fibroblasts and leukocytes 
(Watson and Khaled 2008). The branching epithelial structures are mammary 
ducts that are comprised of two-layers of epithelial cells, with the apical layer 
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called the luminal cells and the basal layer called the myoepithelial cells 
(Muschler and Streuli 2010). One end of a mammary duct connects to a major 
duct that directs to the nipple, and the other end forms lobular-shape ends, which 
are called terminal end buds (TEBs) (Hennighausen 1997). Mammary branching 
morphogenesis occurs during puberty and pregnancy. During each cycle of 
pregnancy, the ductal epithelial cells undergo extensive directed proliferation in 
the form of iterative branching (Hennighausen 1997; Muschler and Streuli 2010). 
These newly formed branches invade into and fill the mammary fat pad 
(Hennighausen 1997; Muschler and Streuli 2010). Branching morphogenesis is 
controlled by estrogen, progesterone and other hormones produced by the 
placenta (Hennighausen 1997). The luminal cells differentiate into milk-producing 
alveolar cells in response to a decrease in estrogen and progesterone and 
increase in prolactin, insulin, and glucocorticoids (Hennighausen 1997). Upon 
weaning, the mammary gland undergoes involution, a process that involves 
collapse of the alveoli by the removal of the secretory epithelial cells and other 
epithelial cells through apoptosis and phagocytosis and extensive degradation of 
ECM and the basement membrane (BM) (Hennighausen 1997; Muschler and 
Streuli 2010). Then, the mammary gland reverts back to the pre-pregnant state.  
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EMT and Mammary Epithelial Biology 
Epithelial to mesenchymal transition (EMT) is a physiological and pathological 
process that enables the dynamic transition of a cell with an epithelial fate to a 
mesenchymal fate (Yang and Weinberg 2008; Thiery et al. 2009; Scheel et al. 
2011). This process involves the repression of the key epithelial gene, E-
cadherin, which mediates cell-cell adhesion, and the induction of mesenchymal 
genes including vimentin and smooth muscle actin (SMA) (Cano et al. 2000; 
Valcourt et al. 2005; Thiery et al. 2009; Vuoriluoto et al. 2011). Activation of 
specific signaling pathways, especially TGF-β signaling (Valcourt et al. 2005), 
and the active involvement of transcription factors including Snai1/2 (Batlle et al. 
2000; Cano et al. 2000; Guo et al. 2012; Liu et al. 2012), Twist (Yang et al. 
2012a), Zeb1/2 (Shirakihara et al. 2007; Drake et al. 2009; Chaffer et al. 2013), 
and Goosecoid (Hartwell et al. 2006), have been identified as triggers of the EMT. 
Importantly for this thesis, the EMT also involves changes in the expression of 
specific integrins as will be discussed below. 
The EMT contributes to mammary gland development. During branching 
morphogenesis, elongation of the mammary branches is led by proliferation of 
the epithelials cells in the TEB (Micalizzi et al. 2010). These epithelial cells 
transiently obtain mesenchymal features, including loss of apical-basal polarity 
(Ewald et al. 2012), and elevated expression of the EMT transcription factors 
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Snai1 and Twist (Kouros-Mehr and Werb 2006). Also, secretion of matrix 
proteinase, MMP3, by the stroma cells that surround TEB, is necessary for 
efficient branching morphogenesis (Wiseman et al. 2003). Importantly, MMP3 
promotes EMT in vitro (Radisky et al. 2005). However, administering exogenous 
TGF-β (a strong EMT inducing growth factor) resulted in reduced branches 
(Robinson et al. 1991), suggesting that branching morphogenesis does not 
involves a complete EMT program. Instead, a partial EMT (gaining partial 
mesenchymal features with some epithelial characteristics maintained) has been 
proposed to occur during mammary gland development (Micalizzi et al. 2010; 
Nakaya and Sheng 2013). 
 
Breast Cancer Overview and Subtypes 
Breast cancer histology and pathology: Breast cancer can be viewed as the 
abnormal proliferation of breast epithelial cells (tumor) and carcinoma associated 
fibroblasts (tumor stroma), and it exists as ductal type or lobular type, with the 
ductal type compromising the majority of cases (40%-75%) (Bombonati and 
Sgroi 2011). Ductal breast carcinoma can be divided into 4 progressive stages 
based on histology: flat epithelial atypia (benign lesion), atypical hyperplasia (pre-
cancerous lesion), ductal carcinoma in situ (DCIS), and invasive ductal 
carcinoma (IDC, which is highly aggressive and metastatic) (Bombonati and 
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Sgroi 2011). However, these histological stages only provide a rough correlation 
with prognosis and response rate to therapy (Polyak 2007; Rivenbark et al. 2013). 
The expression of surface markers including estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2) as assessed by immunohistochemistry has provided improved prediction 
power for prognosis (Rivenbark et al. 2013). The presence of ER and PR usually 
indicates a good prognosis, because these tumors generally respond to hormone 
therapy (Rivenbark et al. 2013). Overexpression of HER2 is associated with 
aggressive behavior of breast cancer (Slamon et al. 1987) resulting from the 
cooperative actions between HER2 and other growth factors (e.g. epidermal 
growth factor receptor 1) (Hynes and Lane 2005; Folgiero et al. 2007). In contrast, 
tumors with a ‘triple-negative’ (ER-/PR-/HER2-) staining pattern are usually 
poorly differentiated and have the worst prognosis (Haffty et al. 2006; Kang et al. 
2008).   
Molecular classification of breast cancer: Since 2000, a molecular classification 
of breast cancer based on gene expression profiles has been emerging. These 
studies have concluded that at least 6 distinct subtypes of breast cancer exist: 1) 
luminal A (ER gene set+ and HER2-), 2) luminal B (reduced ER gene set with 
increased HER2), 3) HER2 type (HER2 gene set+ and ER-), 4) basal-like 
(myoepithelial gene set+ and  ER-/HER2-), 5) claudin-low (epithelial-
mesenchymal transition gene set+ and ER-/HER2-) and 6) normal-like (normal 
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breast epithelial gene set+) (Sorlie et al. 2001; Sorlie et al. 2003; Prat et al. 2010; 
Rivenbark et al. 2013). Among these subtypes, luminal A/B tumors comprise the 
majority of breast cancers (50%) (Rivenbark et al. 2013), and they are generally 
associated with good prognosis; while basal-like, claudin-low and HER2 tumors 
are much more aggressive (Sorlie et al. 2001; Sorlie et al. 2003; Prat et al. 2010).  
Targeted therapy: Over the last two decades, the treatment for breast cancer has 
improved, with the mortality rate decreasing by 24%, as a result of the success of 
targeted therapy in ER+ and HER2+ patients (Bombonati and Sgroi 2011; 
Rivenbark et al. 2013). However, further advances in the treatment of breast 
cancer are hindered by: 1) lack of therapeutic targets for triple negative breast 
cancer and 2) the limited long-term efficacy of targeted therapy in ER+ and 
HER2+ patients (Hynes and Lane 2005; Polyak 2014). The next breakthrough in 
the breast cancer treatment requires further understanding of the nature of 
disease progression and heterogeneity, which leads to a discussion of breast 
CSCs. 
 
Breast cancer stem cells 
Mammary tumors are inherently heterogeneous (Prat et al. 2010; Rivenbark et al. 
2013; Polyak 2014). For example, in a study examining multiple sites within DCIS 
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(ductal carcinoma in situ) specimens, researchers found that 72% of DCISs 
harbor more than one pathological staining pattern (defined by ER, PR, HER2) 
(Pape-Zambito et al. 2014). This result indicates that distinct molecular subtypes 
reside within one disease. Why is breast cancer heterogeneous? One prevailing 
hypothesis is that breast cancer stem cells (CSCs) can give rise to progenies 
with differential molecular traits (Polyak 2007; Visvader 2009). 
The identification of mammary stem cells contributed to the initial 
identification of breast CSCs (Lu et al. 2012; Lane et al. 2014). More specifically, 
the CSC hypothesis implies that tumors are generated and maintained by a small 
“stem cell” population that is slow-cycling and resistant to stress and apoptosis, 
and this population is able to self-renewal and regenerate a bulk tumor (Visvader 
and Lindeman 2008; Charafe-Jauffret et al. 2009). These characteristics 
resemble normal stem cells (Jordan et al. 2006). 
The first breast CSC enriched population was identified in 2003. In this 
study, 200 tumor cells with the specific surface markers (Lineage negative/ CD44 
high/ CD24 low/ Epcam positive) were sufficient to initiate tumors in NOD/SCID mice 
(Al-Hajj et al. 2003). Subsequent studies have identified CSCs by markers 
(CD44+/CD24-, ALDH1+) (Al-Hajj et al. 2003; Charafe-Jauffret et al. 2009), in 
vitro assays (mammosphere forming ability in serial passages and capacity to 
actively export dye- ‘side population’) or in vivo assays (injecting a defined 
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number of cancer cells into immunodeficient mice and determining the minimal 
number of cells required or minimal time required to initiate tumor formation) 
(Charafe-Jauffret et al. 2009). The CSC population identified in these studies 
usually contains some, but not all, of the above mentioned CSC characteristics, 
and the concept of CSC has been evolving. An intriguing fact is that the factors 
that define normal mammary stem cells do not fully apply to breast CSCs, and 
some positive factors (e.g. CD24 expression) for mammary stem cells are 
negative factors for breast CSCs (Stingl et al. 2006; Pece et al. 2010). In another 
words, breast CSCs are not simply stem cells with oncogenic mutations.  
Breast CSCs and EMT: In 2008, the Weinberg group demonstrated that the EMT 
induced by either TGF-β or transcription factors could generate a CD44 high/CD24 
low
 population, from the CD44 low/ CD24 high population (Mani et al. 2008). These 
CSCs exhibit a gene expression profile similar to mammary stem cells and they 
are able to initiate tumors quite efficiently (Mani et al. 2008). Later, multiple 
studies confirmed the link between EMT and breast CSCs (Thiery et al. 2009; 
Scheel et al. 2011; Chaffer et al. 2013). Interestingly, the claudin-low subtype of 
breast cancer, which is associated with a tumor initiation gene set (CD44+, 
CD24-, EpCAM-, CD10+, CD29+, MUC1-, Thy1+, and ALDH1A1+) and poor 
prognosis, has an EMT phenotype (Prat et al. 2010; Rivenbark et al. 2013). 
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Integrins and Mammary Epithelial Biology 
Mammary epithelial cells are in close contact with the basement membrane, and 
integrins serve as indispensible players that connect the epithelial cells to the BM 
(Muschler and Streuli 2010). During the branching morphogenesis that occurs 
during mammary development and pregnancy, the proliferating mammary TEBs 
and side branches invade and migrate into the stroma where they interact with 
other ECM proteins (Muschler and Streuli 2010; Nakaya and Sheng 2013). All 
these events are mediated by integrin and integrin mediated signaling (Muschler 
and Streuli 2010; Nistico et al. 2014). During the involution after weaning, active 
degradation of the alveolus-related ECM occurs, and it results in major changes 
in the integrin mediated signaling (Hennighausen 1997; Muschler and Streuli 
2010). Integrins also have significant roles in the biology of CSCs and breast 
cancer, as will be discussed below. 
 
Integrins: Structure and Function 
Overview: Given that integrins are the focal point of my thesis, a detailed 
introduction to their structure and function is warranted. Integrin were co-
discovered in the 1980s, when research on identifying distinct types of cell 
surface receptors, including ECM receptors of fibroblasts, platelet receptors and 
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receptors on lymphoid and myeloid cells, led to the realization that significant 
common features are shared among these different types of receptors, based on 
conservations in their sequences and functions (Pytela et al. 1985; Springer et al. 
1985; Hemler et al. 1987; Hynes 1987). With the nomenclature of ‘integrin’ 
established in 1986 (Tamkun et al. 1986), integrins have emerged as a 
superfamily of heterodimeric glycoproteins that mediate cell adhesion and 
integrate the extracellular cues with the intracellular machineries (Hynes 2002; 
Srichai and Zent 2010; Anderson et al. 2014).  
The integrin family: Integrins exist as heterodimers of α and β subunits in a 1:1 
molar ratio, and 18 α and 8 β known subunits constitute a total of 24 integrin 
dimers in mammals (Hynes 2002; Srichai and Zent 2010). Each integrin 
heterodimer has specific ligands that are the components of the extracellular 
matrix, which is a collection of proteoglycans, hyaluronic acid, and proteins (e.g. 
collagen, fibronectin, vitronectin and laminin) that surrounds cells providing 
essential structural and biochemical support (Pickup et al. 2014). Specifically, 
α1β1, α2β1, α10β1, α11β1 are the major receptors for collagens; α3β1, α6β1, 
α7β1 and α6β4 are the major receptors for laminins; αvβ3, αvβ5, αvβ6, αvβ8, 
αIIbβ3, α5β1 and α8β1 are primary receptors of fibronectin or vitronectin via the 
R-G-D sequences in these ligands. Also, αDβ2, αLβ2, αMβ2, αXβ2, α4β7 and 
αEβ7 are leukocyte-specific integrins, whose primary ligands are immuno cell-
specific molecule, ICAM (Hynes 2002; Takada et al. 2007; Srichai and Zent 
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Anderson et al. 2014). The structure of β-subunit consists of a βI domain that is 
structurally similar to aI as the head domain, a hybrid domain, a PSI (plexin-
semaphorin-integrin) domain, four EGF repeats, a β tail domain, then a single TM 
domain, and a short cytoplasmic tail (with the exception of β4 subunit, which has 
a long cytoplasmic tail of more than 1000 AAs) (Tamura et al. 1990; Srichai and 
Zent 2010; Anderson et al. 2014). When the αI domain is absent in the α subunit, 
the βI domain is crucial for ligand binding (Srichai and Zent 2010). Other than β4, 
the cytoplasmic tails of β subunit are highly conserved with a membrane-proximal 
NPxY motif and a membrane-distal NxxY motif, which serve as the recognition 
sequences for the phosphotyrosine-binding (PTB) domain containing adaptor 
proteins (Calderwood et al. 2003; Srichai and Zent 2010). The pair of these two 
motifs is a crucial hub for multiple adaptor proteins, particularly talin and kindlin, 
which connect integrins to the intracellular machinery (Montanez et al. 2008; 
Moser et al. 2008; Legate et al. 2009; Srichai and Zent 2010). 
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subsequent signal transmission from the outside to the inside (Srichai and Zent 
2010; Anderson et al. 2014).  
Bidirectional signaling by integrins: Integrins transfer bidirectional signals, which 
are referred as “inside-out” and “outside-in” signaling (Hynes 2002; Srichai and 
Zent 2010). Generally, integrins are unable to activate themselves. Instead, they 
rely on the binding of intracellular adaptor proteins that associate with the β tail 
(Srichai and Zent 2010). This association induces a major conformational change 
that leads to integrin activation by increasing the ligand affinity on the 
extracellular side (Srichai and Zent 2010). The first key adaptor protein identified 
that activates integrins is talin, which binds the β tail through the NPxY motif-PTB 
domain interaction (Calderwood et al. 1999; Calderwood et al. 2002; Srichai and 
Zent 2010). However, talin itself is normally auto-inhibited with its C-terminus 
masking the talin PTB domain (Ratnikov et al. 2005). This blockage is released 
by increased local PIP2 (phosphotidylinositol-4, 5-bis-phosphate) loaded on talin 
(Srichai and Zent 2010). In addition, Src family kinases can phosphorylate the Y 
in the NPxY motif of the β tail and promote talin-integrin interactions (Sakai et al. 
2001). The second key adaptor is kindlin, which binds the NxxY motif of the β 
subunit, immediately after talin binds to the β tail (Montanez et al. 2008). Kindlin 
cooperates with talin to further enhance integrin affinity for its ligands (Ma et al. 
2008; Montanez et al. 2008; Moser et al. 2008). All these processes lead to 
integrin activation by talin and kindlin and contribute to “Inside-out” signaling.  
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When activated and clustered, integrins nucleate the focal adhesion (FA) 
complex, a large and dynamic protein matrix composed of more than 150 
intracellular proteins (Zaidel-Bar et al. 2007; Srichai and Zent 2010). The FA 
serves as the connection platform that links the 1) cytoskeleton, including actin 
fibers and microtubule bundles, and 2) its modulating machinery, including 
Arp2/3 complex and Rho GTPases with integrins (Jaffe and Hall 2005; Srichai 
and Zent 2010). Thus the FA links the extracellular signal sensed by the integrin 
with alterations in the cytoskeleton and performs the “outside-in” function. For 
example, α3β1 integrin activates the Rho GTPase, Rac1, to promote 
keratinocyte polarization via the FAK/Src complex (Choma et al. 2007). In 
addition to the link with cytoskeleton, the formation of the FA complex also 
recruits and activates several kinases, which serve as intersecting points 
between integrin signaling and growth factor signaling pathways (Srichai and 
Zent 2010). The focal adhesion kinase (FAK) and non-receptor tyrosine kinase 
Src are among the kinases activated by integrin clustering (Srichai and Zent 
2010). Activated FAK and Src form a complex that activates or amplifies several 
signaling pathways related to growth (Schlaepfer and Hunter 1996; Srichai and 
Zent 2010). One well-characterized pathway is the mitogen-activated-protein-
kinase (MAPK) pathway. Pak1, the upstream trigger for the MAPK signaling 
cascade, is a substrate of the FAK-Src complex (Srichai and Zent 2010). As a 
result, integrin activation can increase the signaling intensity of MAPKs through 
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FAK. One example for this mechanism is that cells can activate ERK (one type of 
MAPKs) to survive in serum-free conditions (low growth stimuli), through the 
integrin activation of α3β1 by plating cells on its ligand laminin-5 (Manohar et al. 
2004). Importantly, this survival effect is also dependent on the core player of 
integrin signaling, FAK (Manohar et al. 2004). Other growth factors signaling 
pathways have also been shown to be intensified by integrin activation, which is 
reviewed elsewhere (Tamura et al. 1990; Hynes 2002; Watt 2002; Lipscomb and 
Mercurio 2005; Wilhelmsen et al. 2006; Srichai and Zent 2010).  
Summary of the general functions of integrins: Integrins contribute to a broad 
range of cellular activities. Adhesion and migration are complex and integrated 
processes that involve both alterations in the cytoskeleton and local intracellular 
signals (Anderson et al. 2014). As stated above, integrins are indispensible 
players in these processes. Invasion, which is a special type of cell migration that 
couples migration with the active secretion of the matrix metalloproteases, also 
involves integrins. For example, α3β1 integrin can induce MMP-9 (matrix 
metallopeptidase 9) in immortalized cells, by increasing the MMP-9 mRNA 
stability (Iyer et al. 2005; Lamar et al. 2008). Furthermore, cell survival, 
proliferation and differentiation are integrin-mediated processes, because growth 
factor signaling and intracellular signaling pathways (e.g. MAPK and PI3K) 
involved in these processes depend on integrin-mediated outside-in signaling 
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(Watt 2002; Lipscomb and Mercurio 2005; Wilhelmsen et al. 2006; Srichai and 
Zent 2010). 
 
The α6 integrins 
Discovery: The α6 integrin was identified from the surface proteins of platelets, 
and it was initially named VLA6 “very late antigen”, because it was the 6th distinct 
VLA protein (Hemler et al. 1988). The VLA6 integrin was found to heterodimerize 
with the common VLAβ subunit, which also associates with the VLA1-5 α subunit, 
and is now called the β1 integrin subunit (Hemler et al. 1987; Hynes 1987). One 
year later, researchers found that α6 integrin subunit is able to heterdimerize with 
a novel β integrin subunit, the β4 subunit (Kajiji et al. 1989). Thus, α6 has two 
binding partners: β1 (α6β1 integrin) and β4 (α6β4 integrin). 
α6 integrins are important for epithelial biology: Although first discovered in 
platelets, it is now known that a wide variety of cell types express the α6 integrin: 
fibroblasts (Chen et al. 2001), endothelial cells (Leu et al. 2003), leukocytes and 
epithelial cells (Shaw et al. 1990). The α6 integrin is particularly important for 
epithelial biology because: 1) it is expressed in almost all normal and tumor 
epithelial cells (Hemler et al. 1989; Hogervorst et al. 1993); 2) complete knockout 
of α6 is lethal at the neonatal stage, because of severe blistering of the skin and 
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other epithelia (Georges-Labouesse et al. 1996). These epithelial fragilities are 
associated with the absence of α6β4 integrin, a key protein anchoring the 
epithelial cells on the BM (Georges-Labouesse et al. 1996). Human hereditary 
diseases that carry either homozygous missense or frameshift mutations in the 
α6 gene also cause skin fragility (epidermolysis bullosa) and obstruction in the 
gastric outlet (pyloric atresia) (Pulkkinen et al. 1997; Ruzzi et al. 1997). 
α6 splice variants: Shortly after its identification, it was shown that α6 exists as 
two splice isoforms, α6A and α6B (longer isoform), which differ only in their 
cytoplasmic tails (Hogervorst et al. 1991) (Fig 1.3). Generation of these isoforms 
occurs by alternative splicing of the last 3 exons (exons 24-26) of the α6 gene: 
α6A contains all 3 exons with translation stopped in the 25th exon and α6B omits 
Fig 1.3 
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the 25th exon and uses the 26th exon for its last part of translation. The splicing 
factor ESRP1 mediates the inclusion of the 25th exon that generates the α6A 
splice variant (Warzecha et al. 2010; Goel et al. 2014). The EMT has been 
shown to suppress the expression of ESRP1 splicing factor and shift the α6 
integrin subunit from A form to B form (Warzecha et al. 2010; Shapiro et al. 2011; 
Goel et al. 2014).  
Despite the fact that two isoforms of α6 display equal capacity to bind β1 
and β4, α6A and α6B exhibit specific expression patterns in some tissues 
(Hogervorst et al. 1993). α6A is the major isoform in epidermis, mammary gland, 
peripheral nerve and smooth muscle cells, while α6B is the major isoform in 
kidney and undifferentiated embryonic stem cells (Hogervorst et al. 1993). 
Functionally, α6Aβ1 and α6Bβ1 have functional overlaps and divergences. Both 
α6Aβ1 and α6Bβ1 are able to associate with the FA complex and mediate focal 
adhesions (Hogervorst et al. 1993). α6Aβ4, but not α6Bβ4, is found in the HD 
(hemidesmosome) -like structures (Hogervorst et al. 1993). α6Aβ1 is also the 
major target for PMA mediated α6 phosphorylation (Hogervorst et al. 1993). Also, 
the PMA-mediated adhesion of macrophages to LM111 is much stronger via the 
α6Aβ1 than the α6Bβ1 integrin (Shaw and Mercurio 1994). However, few studies 
are present on distinct functions of α6B, until the recent finding that α6B is 
associated with the breast CSCs, as described below. 
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Regulation of α6 integrins by tetraspanin CD151: The tetraspanin family protein, 
CD151, constitutively associates with the α6 subunit (Yang et al. 2008). The fact 
that loss of CD151 impairs the normal spatial molecular organization of α6 
indicates that CD151 affects α6 function (Yang et al. 2008). Several α6 integrin-
mediated functions in breast epithelial and carcinoma cells, including adhesion to 
laminin, migration and invasion, also depend on CD151 (Yang et al. 2008). It was 
shown later that CD151 affects α6 integrin signaling by ensuring its proper 
diffusion on the cell surface. In cells that have lost CD151, the diffusion mode of 
α6 subunit shifts from “random and confined diffusion” toward “directed motion” 
(DMO) (Yang et al. 2012b). The DMO diffusion mode of α6 severely impairs its 
ability to concentrate on newly formed focal adhesions, possibly due to a lack of 
efficient recycling of the integrin in this mode of diffusion (Yang et al. 2012b).  
Expression and function of the α6β1 integrin: The α6β1 integrin has specific 
expression patterns. In monocytes, platelets, endothelial cells, fibroblasts, and 
certain breast cancer cell lines, α6β1 integrin is the major integrin that mediates 
the function of α6: very little β4 integrin subunit is present in these cells (Hemler 
et al. 1989).  
The α6β1 integrin function largely involves the FA complex that links the 
cytoskeleton and intracellular signaling, as stated above (Hogervorst et al. 1993; 
Chen et al. 2001). Ligation of α6β1 integrin with its ligands activates FAK by 
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phosphorylation (Chen et al. 2001; Yang et al. 2008). Since FAK plays a central 
role in FA complex function, the α6β1 integrin ligation is able to trigger 
subsequent cytoskeleton rearrangement by the Rho GTPase Rac and the MAPK 
signaling pathway (Chen et al. 2001; Srichai and Zent 2010). These effects 
enable the α6β1 integrin to mediate the adhesion and migration function of the 
cells to laminin substrates and other minor substrates (CCN family proteins 
(Chen et al. 2001), thrombospondin 1 and 2 (Calzada et al. 2003)) that are 
specific to α6β1. The α6β1 integrin is also able to suppress p53-mediated 
apoptosis and promote metastasis in breast cancer (Wewer et al. 1997).  
In the context of mammary stem cells, high α6 or β1 integrin subunit 
surface expression characterizes the stem cell population (Shackleton et al. 2006; 
Stingl et al. 2006). These stem cell-enriched populations are able to regenerate a 
functional mammary gland in the cleared mammary fat pads of mice (Shackleton 
et al. 2006). Thus, it is highly suggestive that α6β1 integrin, rather than α6β4 
integrin, plays critical functions in mammary stem cell maintenance. 
Although breast CSCs differ from normal mammary stem cells, three 
independent studies have shown that high α6 subunit expression is characteristic 
of breast CSCs and important for their function (Cariati et al. 2008; Jo et al. 2010; 
Yu et al. 2012b). Furthermore, recent studies from our lab defined a VEGF 
receptor, Neuropilin 2 (Nrp2), as a novel marker of breast CSCs (Goel et al. 
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2013). Importantly, Nrp2 assoicates with α6β1 (Goel et al. 2012). When isolated 
primary breast tumor cells were sorted by Nrp2, the Nrp2-high population 
correlates with the α6-high and β1-high populations, but negatively correlates 
with β4-high population (Goel et al. 2012; Goel et al. 2014). These data further 
indicates that α6β1, rather than α6β4 integrin, is important for breast CSCs.  
Recent studies have shown that the EMT not only generates properties of 
breast CSCs but also induces a splicing program that involves the shifting from 
α6A splice isoform to α6B splice isoform by suppressing the splicing factor 
ESRP1 (Warzecha et al. 2010; Shapiro et al. 2011). In accordance with these 
findings, our lab has demonstrated that within the putative breast CSC population 
(CD44high/ CD24low), two distinct populations distinguished by their level of 
surface α6 expression level exist: an α6Bβ1-enriched population with strong CSC 
properties and an EMT phenotype; an α6Aβ4-enriched population with weak 
CSC properties and an epithelial phenotype (Goel et al. 2014). Moreover, ectopic 
expression of the α6B subunit is sufficient to drive the CSC properties, while α6A 
cannot do so. These data refined the breast CSC characterization using the 
specific splice variant of α6, α6B, and dictated a specific role of α6Bβ1 in 
promoting breast CSC (Goel et al. 2014). Specific ligand for α6Bβ1 that mediates 
CSC function was not known. It was also not known what intracellular signaling 
pathways triggered by α6Bβ1 specifically regulate breast CSCs. 
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Apart from its role as a structural component of HDs, the β4 integrin can 
function as a signaling protein to promote migration, invasion and survival 
(Lipscomb and Mercurio 2005). Interestingly, this process involves its ability to 
mobilize from HDs and associate with F-actin (Rabinovitz and Mercurio 1997; 
Rabinovitz et al. 1999; Lipscomb and Mercurio 2005; Wilhelmsen et al. 2006). 
For example, EGF treatment of A431 cells induces the mobilization of β4 from 
the HD to F-actin, enabling it to promote cell migration and invasion (Rabinovitz 
et al. 1999). This mobilization of β4 involves activation of PKC-α kinase and 
phosphorylation of Serine residues 1356, 1360, 1364 within the CS domain of the 
β4 cytoplasmic tail (Rabinovitz et al. 2004).  
When mobilized from the HD and functioning as a signaling protein, β4 
integrin is able to activate PI3 Kinase (PI3K) through the tyrosine phosphorylation 
on the 1494 residue (Shaw et al. 1997; Shaw 2001). This phosphorylation is 
mediated by the adaptor protein IRS2 (Insulin Receptor Substrate 2), or other 
unknown factors induced by the growth receptor activation (Shaw 2001; 
Wilhelmsen et al. 2006). PI3K activation increases PIP3 (phosphatidylinositol 
(3,4,5)-trisphosphate), which then activates it key downstream effector, Akt, by 
phosphorylation on its Thr308 and Ser473 residues (Bader et al. 2005). Activated 
Akt can further trigger 1) the growth signaling by activating the mTOR complex 
and 2) promoting survival signal via inhibition of the apoptotic factor p53 by 
MDM2 or activation of the NFκB signaling pathway (Bader et al. 2005).  
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These effects of PI3K activation are important mechanisms for β4 
mediated signaling, including promoting survival, growth (to a lesser extent), 
migration and invasion (Shaw et al. 1997; O'Connor et al. 1998; Lipscomb and 
Mercurio 2005; Wilhelmsen et al. 2006). Also, it has been shown that the β4 
signaling increases the translation of VEGF protein as a result of increased 
mTOR activity by PI3K activation (Chung et al. 2002). Since VEGF signaling also 
activates PI3K-Akt (Wilhelmsen et al. 2006), this mechanism implicated an 
autocrine loop that maintains high PI3K and Akt activities in the carcinoma cells, 
which is mediated by the β4 integrin. Furthermore, several growth factor 
receptors (EGFR, c-Met) or orphan receptor (HER2) have been reported to 
interact with β4 signaling directly and indirectly and thus β4 has been also 
thought as an amplifier for these growth signals (Mariotti et al. 2001; Trusolino et 
al. 2001; Lipscomb and Mercurio 2005; Guo et al. 2006). The signaling functions 
of β4 have been linked to the involvement of this integrin in the survival, invasion 
and metastasis of breast carcinoma cells. 
Although much is known about the functions of β4, little is known about 
mechanisms that regulate its expression, especially its transcription. In contrast 
to the universal distribution of β1 integrins, the β4 integrin exhibits a more 
restricted pattern of expression (Hemler et al. 1989). In the normal mammary 
gland, the β4 integrin is restricted to the basal cell layer, which is composed of 
myoepithelial cells and a few luminal cells (Yang et al. 2009). This observation is 
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consistent with the role of β4 in HD formation, since HD only exists as the 
connection point that links the basal cell layer with the BM. Very little, if any, 
luminal cells express the β4 integrin (Yang et al. 2009). In breast cancer, the β4 
expression pattern is very heterogeneous. One study showed that β4 integrin 
expression tends to decrease in primary breast carcinomas, but heterogeneous 
β4 expression patterns were seen in metastatic sites (Natali et al. 1992); another 
study found that β4 integrin correlates with basal and triple negative (ER-, PR-, 
and HER2-) subtypes that are generally aggressive, but not with luminal A, 
luminal B or HER2+ breast cancer subtype (Lu et al. 2008). However, even within 
the triple negative breast tumors, β4 expression is heterogeneous. These data 
indicated that the regulation of β4 expression is dynamic and reversible, 
depending on the tumor microenvironment and specific tissue compartments. 
Thus, understanding the mechanisms of the transcriptional regulation of β4 
subunit will unveil important aspects of epithelial biology and breast cancer 
biology.  
 
Laminins 
Overview: α6 integrins are primary receptors for laminin (Hogervorst et al. 1991; 
Srichai and Zent 2010). Laminin (LM) are important extracellular matrix proteins 
that are hetero-trimers composed of the α, β and γ subunits in an equal molar 
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fashion. 5 α subunits, 3 β subunits, and 3 γ subunits have been discovered and 
constitute a repertoire of 16 laminin complexes (Patarroyo et al. 2002). Laminins 
are major components of the BM (Patarroyo et al. 2002). Four major laminins 
exist in the mammary gland: LM111, LM332, LM511 and LM521 (Falk et al. 1999; 
Chia et al. 2007). Both α6β1 and α6β4 are able to mediate cell adhesion to 
LM111, LM511 and LM521 matrixes with similar efficiency, and they are able to 
compensate for one another (Kikkawa et al. 2000). In contrast, LM332 is the sole 
ligand for α6β4 integrin within the HD and it is also required for β4-mediated 
NFκB signaling through Rac1 (Kikkawa et al. 2000; Zahir et al. 2003; Margadant 
et al. 2008).  
Other than the α6 integrins, laminins also have other integrin receptors 
(α3β1, αvβ3, α7β1, α1β1 and α2β2) and non-integrin receptors (α-dystroglycan, 
laminin receptor 1, Lutheran glycoprotein receptors, and syndecans) (Givant-
Horwitz et al. 2005; Durbeej 2010). Some of these non-integrin receptors have 
been shown to complex with α6 integrins (Givant-Horwitz et al. 2005).  
 
Laminins and cancer: Changes in the expression and distribution of laminins 
occur in cancer. For example, loss of LM111 expression or its weak deposition 
pattern is observed in human breast cancer (Patarroyo et al. 2002; Chia et al. 
2007). This could be attributed to the ability of LM111 to induce polarity in luminal 
breast epithelial cells, because carcinoma cells often de-polarize during 
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progression (Patarroyo et al. 2002). In contrast, LM332, LM511 and LM521 do 
not induce polarity (Patarroyo et al. 2002). 
Deregulated LM332 in the ECM is also common in epithelial cancers, 
including breast cancer (Patarroyo et al. 2002). On one hand, some studies 
concluded that carcinomas express elevated LM332 based on the staining 
results of γ2 as indicator of LM332 (Miyazaki 2006). These observations are 
plausible, because LM332 can mediate cell migration, invasion, and survival via 
its integrin receptors: α3β1, α6β1 and α6β4 (Miyazaki 2006). On the other hand, 
other studies found that intact LM332 complexes, which are found in the normal 
BM, are lost in the invading area of tumor cells. Rather, these tumor cells only 
express the γ2 subunit as a substitute for the LM332 signaling (Patarroyo et al. 
2002; Miyazaki 2006). It has been proposed that signaling by γ2 promotes cell 
migration and inhibits cell adhesion (Miyazaki 2006). Considering the fact that 
carcinoma cells can synthesize and secrete their own LM111, LM332 and LM511 
and use these laminins as materials for their own ECM in vitro (Patarroyo et al. 
2002), it is conceivable that carcinoma cells can impact the laminin composition 
and distribution within tumor ECM.  
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Rational for the thesis work 
Given the crucial roles of α6 integrins in various aspects of mammary gland 
differentiation, mammary epithelial biology and breast cancer progression, many 
previous studies focused on correlating α6 expression level with the phenotypes 
of breast cancer (Cariati et al. 2008; Yu et al. 2012b). However, the provocative 
finding by our lab clearly indicated that the splice variant of this integrin, rather 
than its expression, determines its ability to promote the functions of breast 
CSCs and tumor initiation (Goel et al. 2014). In addition, is there a specific 
signaling pathway promoted by α6Bβ1 that mediates CSC function? Also, what is 
the specific ligand for α6Bβ1 splice variant? These important questions prompted 
me to initiate the work described in the first chapter of the thesis, which aimed to 
understand the mechanism of how the α6Bβ1 integrin splice variant contributes 
to breast CSC. I initiated the project by comparing the CSC population that 
expresses predominantly the α6B subunit with the non-CSC population that 
expresses predominantly the α6A subunit by deep sequencing of their RNA 
profiles. The results obtained enabled me to formulate and test hypotheses 
aimed at understanding how a6Bb1 contributes to breast CSCs.  
In the second chapter of my thesis, I focused on studying the mechanisms 
that regulate β4 transcription. In previous work, our lab demonstrated that β4 is 
subject to epigenetic regulation (Yang et al. 2009). Specifically, this work showed 
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that the β4 transcription correlated well with changes in histone marks (active 
histone marks H3K4Me3/H3K9Ac and inhibitory histone mark H3K27Me3) but 
not with DNA methylation status (Yang et al. 2009). In order to identify potential 
factors that mediate β4 transcription and these epigenetic changes, I used an 
EMT model that is highly responsive to TGF-β-induced-EMT. This model has 
been proven to be a dynamic system for studying the regulation of β4 
transcription because the EMT represses β4 transcription and the reversal of 
EMT, a process termed MET, reactivates β4 transcription (Yang et al. 2009). 
Thus, the second project of my thesis was initiated by comparing the gene 
expression profiles of the “EMT” NMuMG cells and that of the control or the “MET” 
NMuMGs. Based on these comparisons I aimed to identify specific transcription 
factors that control β4 transcription and histone modifications and to investigate 
the mechanisms involved. 
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Chapter II 
A Laminin 511 Matrix is Regulated by TAZ and Functions as the Ligand for 
the α6Bβ1 Integrin to Sustain Breast Cancer Stem Cells 
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Abstract 
Understanding how the extracellular matrix impacts the function of cancer stem 
cells (CSCs) is a significant but poorly understood problem. We report that breast 
CSCs produce a laminin (LM) 511 matrix that promotes self-renewal and tumor 
initiation by engaging the α6Bβ1 integrin and activating the Hippo transducer 
TAZ.  Although TAZ is important for the function of breast CSCs, the mechanism 
is unknown.  We observed that TAZ regulates the transcription of the α5 subunit 
of LM511 and the formation of a LM511 matrix.  These data establish a positive 
feedback loop involving TAZ and LM511 that contributes to stemness in breast 
cancer.  
 
Introduction 
Most tumors contain a distinct population of cells with stem cell characteristics, 
including the ability to self-renew and populate new tumors. This population is 
often referred to as tumor-initiating or cancer stem cells (CSCs) (Al-Hajj et al. 
2003; Baccelli and Trumpp 2012; Visvader and Lindeman 2012). CSCs are likely 
responsible for tumor recurrence in response to therapy and they may contribute 
to metastasis (Dean et al. 2005; Calcagno et al. 2010; Pinto et al. 2013).  For this 
reason, deciphering the mechanisms that generate and sustain CSCs is a 
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problem of paramount importance. This issue has been the focus of intense 
investigation in recent years resulting in considerable advancements in the 
understanding of the nature of CSCs (Visvader and Lindeman 2012; Beck and 
Blanpain 2013; Kreso and Dick 2014) and the realization that their genesis and 
function can be determined by their microenvironment (Scheel and Weinberg 
2012).   Given this surge in CSC biology, it is surprising that the contribution of 
the extracellular matrix (ECM) has not been investigated more rigorously.  
Although the ECM is presumed to impact the genesis and function of CSCs 
(Lane et al. 2014; Wong and Kumar 2014), much remains to be learned about 
the nature of this involvement and the mechanisms involved.   
The α6β1 integrin is an established marker of breast and other CSCs 
(Goel et al. 2013) (Lathia et al. 2010; Goel and Mercurio 2013). Recently, 
however, we discovered that the α6Bβ1 integrin, a specific splice variant of the 
α6 cytoplasmic domain, is a determinant of breast CSC function, a function that 
cannot be executed by α6Aβ1, the other α6 splice variant (Goel et al. 2014) 
(Seguin et al. 2014).  Given that the α6 integrins function primarily as laminin (LM) 
receptors (Mercurio 1990), this finding implies that α6Aβ1 and α6Bβ1 differ in 
their response to LM matrices and that a specific LM functions as the preferred 
ligand for α6Bβ1 to sustain CSC function.  This hypothesis is consistent with a 
large body of literature implicating the LMs in mammary gland biology and breast 
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cancer, e.g., (Streuli et al. 1995; Pouliot and Kusuma 2013).   The challenge here 
is to identify LM(s) that regulate α6Bβ1 specifically and to elucidate the 
mechanisms by which the LM/α6Bβ1 interaction contributes to the function of 
breast CSCs.  In pursuit of this problem, we discovered that LM511 is associated 
with α6Bβ1 and functions as the preferred ligand for this splice variant.  
Importantly, we observed that high LM511 expression and the formation of a 
LM511 matrix niche characterize breast CSCs.  Our data also reveal that 
LM511/α6Bβ1 activate the Hippo transducer TAZ, which has been implicated in 
the function of breast CSCs (Cordenonsi et al. 2011), providing a novel 
mechanism for LM regulation of CSC function.  Unexpectedly, we discovered that 
the α5 subunit of LM511 is a TAZ target gene and that TAZ regulates the 
formation of a LM511 matrix, establishing one mechanism for how TAZ 
contributes to CSC function. 
 
Results 
Breast CSCs produce a LM511 matrix that functions as the ligand for the α6Bβ1 
integrin to promote self-renewal and tumor initiation: The goal of this study was to 
identify the α6Bβ1 ligand that enables this integrin splice variant to promote self-
renewal and initiate new tumors, and to determine the mechanisms involved.  We 
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used two model systems initially to achieve this goal. The CD44+/CD24- 
population isolated from Src-transformed MCF10A cells (Iliopoulos et al. 2011) 
consists of distinct epithelial (EPTH) and mesenchymal (MES) populations that 
differ in the relative expression of the α6A and α6B splice variants and stem cell 
properties (Goel et al. 2014).  Specifically, the MES population is enriched in 
α6Bβ1 expression and exhibits self-renewal and tumor initiating ability compared 
to the EPTH population, which is enriched for α6A integrin expression.  We also 
engineered SUM1315 cells to express either the α6Aβ1 or α6Bβ1 splice variants 
at equivalent levels of surface expression and demonstrated that α6Bβ1-
expressing cells exhibit cancer stem cell properties in comparison to α6Aβ1-
expressing cells (Goel et al. 2014).  The gene expression profiles of the EPTH 
and MES populations were compared by RNA-sequence analysis (RNA-seq) 
(Table S2.1).  The data obtained revealed distinct differences in the expression 
of specific LM subunits between these populations, which we confirmed by real-
time PCR (qPCR).  Specifically, the MES population and the α6Bβ1-expressing 
SUM1315 cells exhibited a significant increase in the mRNA expression of the 
LMα5 and LMβ1 subunits and a concomitant decrease in the LMα3, LMβ2, LMβ3 
and LMγ2 subunits (Fig. 2.1A). These results were corroborated by 
immunoblotting (Fig. 2.1B). 
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 The LMα5 subunit is a component of LM511 and LM521 (Aumailley et al. 
2005; Miner 2008).  The fact that LMβ2 expression is repressed in the MES and 
α6Bβ1/SUM1315 cells infers that LM511 correlates with α6Bβ1 expression and 
stem cell properties, and that it appears to be the preferred ligand for α6Bβ1.  To 
assess this hypothesis, we assayed adhesion to LM511, LM111, fibronectin (FN) 
and collagen I (COL I). Indeed, the MES population and the α6Bβ1/SUM1315 
cells adhered better to LM511 than to the other matrix proteins (Fig. 2.1C).  Also, 
the MES and α6Bβ1/SUM1315 cells adhered significantly better to LM511 than 
the EPTH and α6Aβ1/SUM1315 cells (Fig. 2.1C). Titration of matrix protein 
concentration revealed that α6Bβ1-expressing cells adhered much more avidly to 
LM511 than to either LM111 or FN (Fig. 2.1D, left and Fig. S2.1A). More 
definitive evidence to implicate α6Bβ1 as the receptor for LM511 was obtained 
using transcription activator-like effector nucleases (TALENs) to disrupt the 
alternative splicing site in the α6 mRNA, which results in loss of α6B expression 
(Goel et al. 2014). TALEN-mediated depletion of α6Bβ1 inhibited adhesion to 
LM511 without affecting adhesion to LM111 (Fig. 2.1D, right).  Adhesion to 
LM111 was not affected because depletion of α6Bβ1 increases α6Aβ1 (Goel et 
al. 2014), which likely functions as a LM111 receptor. The residual adhesion of 
MDA-231-α6B -TALEN cells to LM511 at a high concentration (5 µg/ml) appears 
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to be mediated by α6Aβ1 because it was inhibited significantly by GoH3, an α6 
inhibitory antibody (Fig. S2.1B). 
 Our data suggest that LM511 is produced by breast CSCs and that it 
functions as the ligand for α6Bβ1 to promote self-renewal and tumor initiation.  
To test this hypothesis, we depleted LMα5 expression in MES cells and observed 
a significant decrease in their adhesion to glass (Fig. 2.1E). The possibility that 
breast CSCs produce a LM511 matrix was substantiated by sorting cells the 
MES using a LMα5 Ab.  This process revealed a relatively small population of 
tumor cells (~2%) that exhibited high surface-bound LMα5 (Fig. 2.1F).   A similar 
approach was used to analyze three primary breast tumors and we found that 
each tumor contained a relatively small population of cells with high surface-
bound LMα5 (Fig. 2.1G).  Importantly, this population has an increased ability to 
form mammospheres (Fig. 2.1G) and expresses more of a mesenchymal marker 
(vimentin) and less of an epithelial marker (E-Cadherin) than the bulk population 
(Fig. S2.1C-D).  Also, IHC staining of breast tumors identified a small number of 
cells that exhibited high LMα5 expression compared to other tumor cells (Fig. 
2.1H).   
Subsequently, we investigated the contribution of LMα5 to self-renewal 
and tumor initiation more rigorously.  The LMα5 blocking Abs (4C7 and 8G9) 
reduced the ability of MES cells to form primary mammospheres, an effect that 
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was synergistic in the presence of both Abs (Fig. 2.2A).  Depletion of LMα5 in 
these cells using shRNAs resulted in a significant decrease in self-renewal as 
assessed by serial passaging of mammospheres (Fig. 2.2B).  Orthotopic injection 
of the shLMα5 cells into the mammary fat pad resulted in a significant increase in 
tumor-free survival compared to control cells (Fig. 2.2C).  We also made use of a 
transgenic model of breast cancer in which the Rb pathways were inactivated in 
the mammary epithelium by the SV40 Large T-antigen (T121), along with 
conditional alleles of p53 and Brca1 (Kumar et al. 2012) (Goel et al. 2013).  
These TgMFT121; Brca1f/f p53f/f; TgWAP-Cre mice (referred to as TBP) develop 
poorly differentiated carcinomas with a triple-negative phenotype (Kumar et al. 
2012).  We isolated a population of cells from TBP tumors (α6high/β1high) enriched 
for cells with stem cell properties (Shackleton et al. 2006) (Stingl et al. 2006), 
which constitute a relatively small fraction of tumor cells (Fig. 2.2D).  This 
population, which expresses α6B, exhibited substantially more LMα5 expression 
and ability to form mammospheres compared to the non-CSC populations (Fig. 
2.2D). The ability of this CSC population to form mammospheres and initiate new 
tumors is dependent on their expression of LMα5 (Fig. 2.2E, F).   
LM511/α6Bβ1 promote TAZ activation: The data provided thus far indicate that 
LM511 is the preferred ligand for α6Bβ1 and that it functions in this capacity to 
promote self-renewal and tumor initiation.  Insight into the mechanism by which 
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LM511 promotes these functions was obtained by analyzing our RNA-seq data 
(Table S2.1).  This analysis revealed that the MES population is enriched for the 
expression of several target genes regulated by the Hippo transducers TAZ and 
YAP (Varelas 2014) compared to the EPTH population (Table S2.1). The 
significance of this observation is supported by the report that TAZ is necessary 
for the function of breast CSCs (Cordenonsi et al. 2011). We confirmed our RNA-
seq data by comparing the expression of TAZ target genes in these populations 
by qPCR (Fig. 2.3A) and determining that TAZ nuclear localization is significantly 
higher in the α6Bβ1-expressing (Fig. 2.3B) and MES cells (Fig. 2.3C) than in the 
EPTH and α6Aβ1-expressing cells.  Interestingly, YAP nuclear localization did 
not differ as much between these populations (Fig. 2.3C).  Also, the activity of 
TEADS, the dominant transcription factors that anchor TAZ on DNA (Varelas 
2014), was significantly higher in α6Bβ1-expressing cells (SUM1315) and MES 
compared to α6Aβ1-expressing (SUM1315) and EPTH cells (Fig. 2.3D and Fig. 
S2.1E). The importance of TAZ in mammosphere formation and self-renewal was 
also confirmed (Fig. 2.3E). 
 More definitive evidence to implicate LM511 in regulating TAZ activity was 
obtained by comparing TAZ nuclear localization and target gene expression in 
cells plated on LM111 and LM511. Clearly, LM511 attachment promotes TAZ 
activation (Fig. 2.3F) and TAZ target gene expression (Fig. 2.3G) more robustly 
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than LM111.  Depletion of LMα5 expression resulted in a significant decrease in 
TAZ nuclear localization and target gene expression (Fig. 2.3H, I).  We also 
validated the contribution of α6Bβ1 to TAZ activation directly by comparing the 
activity of a TEAD reporter construct and expression of TAZ target genes in cells 
in which α6B had been deleted using TALENs (Goel et al. 2014) to control cells 
(Fig. 2.3J, K). Importantly, TALEN-mediated deletion of α6B also prevented 
tumor formation upon orthotopic injection (Fig. 2.3L). 
The regulation of TAZ by LM511 appears to be independent of Hippo 
signaling based on our observations that the ability of LM511 to activate TAZ is 
independent of cell confluence (data not shown) and that knockdown of LATS1 
did not increase LMα5 expression (Fig. 2.3M).  Although we do not exclude the 
involvement of Hippo signaling, our observations are consistent with other 
reports of Hippo-independent YAP/TAZ activation, e.g., (Dupont et al. 2011). 
TAZ regulates LMα5 expression: Although TAZ has been implicated in the 
function of breast CSCs (Cordenonsi et al. 2011), the mechanisms involved have 
not been established.  Given our observation that both TAZ target genes and 
LMα5 are enriched in cells with stem-like properties, we investigated the 
possibility that TAZ regulates LMα5 expression. Indeed, we discovered that 
knockdown of TAZ but not YAP diminished LMα5 mRNA expression significantly 
(Fig. 2.4A, B). This effect was also observed on LMα5 protein expression (Fig. 
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2.4A, B).  These results prompted us to pursue the possibility that LMα5 is a TAZ 
target gene.  We cloned the LMα5 promoter and detected a two-fold increase in 
its activity in MES cells compared to EPTH cells (Fig. 2.4C left).  To establish that 
this differential promoter activity is caused by TAZ, we co-transfected the 
promoter construct with or without exogenous TAZ expression in HEK293 cells, 
and observed that TAZ expression increased promoter activity significantly 
compared to vector control (Fig. 2.4C right).    
TAZ does not have a DNA-binding site and functions as a transcriptional 
co-activator (Kanai et al. 2000).  In silico motif analysis of the LMα5 promoter 
identified multiple TEAD binding motifs (Fig. 2.4D). The TEAD transcription factor 
is the predominant mediator of TAZ function in the Hippo pathway (Varelas 2014).  
ChIP was used to establish binding of TAZ to these TEAD binding sites (Fig. 
2.4D). To control for specificity, no TAZ binding was detected in exons of the 
LMα5 gene (Fig. 2.4D). Exogenous expression of TAZ in the LMα5 low 
population of cells sorted from three PDX tumors was sufficient to increase their 
expression of LMα5 mRNA and ability to form mammospheres significantly (Fig. 
2.4E-F). 
The above findings infer that TAZ regulates the expression of a LM511 
matrix.  To examine this hypothesis, we assessed the impact of TAZ knockdown 
on surface-bound LMα5 by flow cytometry.  As shown in Fig. 2.4G, diminishing 
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TAZ significantly decreased the frequency of the small population of cells with 
high surface-bound LMα5 (see Fig. 2.1F, G). We also found that TAZ knockdown 
reduced the ability of cells to deposit a LM511 matrix in culture (Fig. 2.4H). 
 
Discussion 
In this study, we identified LM511 as the ligand for α6Bβ1 and demonstrate that 
LM511/α6Bβ1 signaling promotes stem cell properties by activating the Hippo 
transducer TAZ. The regulation and function of YAP and TAZ in cancer have 
been the focus of intense investigation (Piccolo et al. 2013; Yu and Guan 2013). 
However, aside from the report that an MT1-MMP/β1 integrin cascade promotes 
YAP/TAZ nuclear localization in skeletal stem cells (Tang et al. 2013), nothing is 
known about ECM/integrin regulation of YAP/TAZ in cancer. For this reason, our 
discovery that breast CSCs produce a LM511 matrix that functions to sustain 
TAZ activation and stem cell properties is a significant advancement that 
highlights the importance of the ECM in regulating Hippo effectors (Yu and Guan 
2013).  Moreover, our data reveal that high LM511 expression is a useful marker 
for identifying tumor cells with stem cell properties and that such cells can be 
isolated by flow cytometry using LMα5 Abs.  
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The second major conclusion of this study is that LMα5 is a TAZ target 
gene and that TAZ regulates the formation of a LM511 matrix.  This conclusion is 
significant because it provides insight into the mechanism by which TAZ 
contributes to the function of CSCs. Indeed, our finding that TAZ contributes to 
the regulation of LMα5 transcription implicates the ECM as a critical effector of 
TAZ-mediated functions. Our data also indicate that breast CSCs generate a 
LM511 matrix using a positive feedback loop that involves LM511/α6Bβ1-
mediated activation of TAZ and TAZ-mediated regulation of LM511. These 
findings imply that breast CSCs generate their own matrix niche that functions to 
maintain stemness by sustaining TAZ activation. 
 
Materials and Methods 
Cells: ER-Src transformed MCF-10A cells were provided by Dr. Kevin Struhl 
(Harvard Medical School, Boston, MA).  Isolation of the CD44+/CD24- population 
from these Src-transformed MCF10A cells and characterization of distinct 
epithelial (EPTH) and mesenchymal (MES) populations have been described 
(Goel et al. 2014).  The generation of SUM1315 cells that express either α6Aβ1 
or α6Bβ1, and the use of TALENs to target the splicing site in the α6 subunit and 
the generation of α6B-depleted cells have also been described (Goel et al. 2014).  
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HEK293 cells were purchased from ATCC.  Flow cytometry was used to analyze 
surface expression of the α6 integrin, CD44 and CD24. 
RNA-sequence analysis: RNA was extracted from the indicated cells and sent to 
Beijing Genomics Institute (BGI) for quantification, sequencing and analysis. 
Sequencing was performed on the single end of the mRNA fragment with a 
reading length of 50bps. Each sample had a sequencing depth of 5 million. 
Matrix proteins and adhesion assays: LM511 was purified from HEK293 cells 
stably expressing human LM511 (LMα5, LMβ1, LMγ1) using HA-agarose beads 
(Pierce). The LM511 was eluted from beads using 100ug/ml HA peptide 
(GeneScript) and dialyzed in buffer (50mM Tris pH 7.4, 90mMNaCl, 0.125mM 
EDTA). Other matrix proteins were purchased from commercial vendors: LM111 
(Life Technologies), fibronectin (Sigma) and collagen I (BD Bioscience). Glass 
coverslips or multi-well plates were coated overnight at 40C with the indicated 
concentration of matrix protein and blocked with 1%BSA at 370C for 30 mins 
before use. Adhesion assays were performed as described previously (Shaw and 
Mercurio 1994) and quantified by crystal violet staining or visual counting of cells. 
RNA interference: The human (TRCN0000119152, 55, 56) and 
mouse(TRCN0000252846, 48) shLMα5 vectors in a PLKO.1-TRC backbone 
were purchased from the UMMS shRNA core facility or Sigma. The lentiviral 
shYAP1 vectors were purchased from Addgene [plasmids #42540 (shYAP-1) 
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and #42541 (shYAP-2)]. The retroviral shTAZ vectors were obtained from 
Addgene (Cordenonsi et al. 2011). Stable expression of these shRNAs was 
obtained by selecting cells in 2ug/ml puromycin for 5-10 days. 
FACS: To quantify surface-bound LMα5, cells in culture were detached, stained 
with a LMα5 Ab (4C7 or 8G9) and analyzed by FACS. Primary breast tumors 
were dissociated into single cell suspensions as described (Goel et al. 2013) 
before staining and FACS analysis. 
Mammosphere assays and xenograft experiments: Mammosphere assays were 
performed as described (Goel et al. 2013). In some experiments, the indicated 
Abs were added to the mammosphere cultures at the time of cell plating. 
Xenograft studies involving the indicated cells were also performed using 
NOD.Cg-PrkdcscidIL2rgtm1Wjl(NSG) mice obtained from the Jackson Laboratory as 
described (Goel et al. 2013). In some experiments, tumor cells were isolated 
from the TBP mammary tumors, manipulated in vitro and used for xenograft 
studies as described (Goel et al. 2013).Tumor onset was determined by 
palpation. 
Patient-derived xenografts (PDX) tumors: Breast tumor tissue (triple-negative) 
samples were obtained from breast cancer surgery patients, through Brigham 
and Women's Hospital and Massachusetts General Hospital. These breast 
tumors samples were cut into small fragments, which were then surgically 
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implanted into the fourth mammary fat pad of NSG mice. Tumor xenografts were 
expanded into multiple recipient NSG mice for several passages. Tumors were 
harvested and analyzed as described in the text. 
Immunostaining: Immunofluorescence microscopy was performed on cells 
adherent to specific matrix proteins as indicated in the figure legends. Cells were 
fixed with paraformaldehyde and permeabilized with Triton X-100 as described 
(Cordenonsi et al. 2011). The following primary Abs were used for staining: TAZ 
Ab (1:100 dilution,560235, BD Biosciences), YAP1 (1:200 dilution, sc-101199, 
Santa Cruz). For LMα5 IF staining of human breast tumors, frozen sections were 
fixed in acetone and immunostaining was performed using 4C7 Ab as described 
(Wondimu et al. 2013). An anti-mouse Cy3 Ab (715-165-150; 1:250 dilution; 
Jackson Immunoresearch) was used as the secondary Ab. 
Immunohistochemistry on frozen sections of human breast tumors was 
performed as described (Wondimu et al. 2013) using the 8G9 LMα5 Ab 
(Wondimu et al. 2013) or IgG control. Human breast tissues were obtained from 
the UMASS Tissue Bank in compliance with our IRB. For staining of deposited 
matrix, cells were cultured for 4 days and detached by incubating in PBS 
containing 25mM EDTA at 40C overnight and the exposed matrix was stained 
using 4C7. 
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Biochemical assays: For qPCR, total RNA was extracted using the Trizol reagent 
(Invitrogen) or RNA isolation kit (Life Technologies) and cDNAs were produced 
using Roche First strand synthesis kit (Roche). qPCR was performed using a 
SYBR green (Applied Biosystems) or TaqMan (Life Technologies) master mix. 
The qPCR primersused are provided in Table S2.2. Data were normalized to 
GAPDH or UBC. Two-tailed Student t-tests were used for statistical comparison. 
For LMα5 immunoblotting, a 4%-5%-10% sandwich gel was used to ensure 
proper separation of the 400kDA LMα5 band.The following antibodies were used 
for blotting: actin (A20660, Sigma), LMα5 (sc-20145, Santa Cruz), LMγ2 (sc-
28330, Santa Cruz), integrin α6B (MAB1358, EmdMillipore), integrin α6A (NBP1-
97690, Novus Biologicals), TAZ (560235, BDBioscience). 
ChIP assays were performed using the ChIP-it express Kit (Active Motif) as 
described (Chang et al. 2013).  Chromatin containing 2ug-6ug DNA/sample was 
immunoprecipitated using 1ug of a TAZ Ab (560235, BD bioscience) or mouse 
IgG.ChIP incubation was performed overnight at 4ºC. The immunoprecipitated 
DNA was then subjected to qPCR analysis using the ChIP primers listed in Table 
S2.2. Two-tailed Student t-tests were used for statistical comparison. To assess 
the activity of the human LMα5 promoter, a genomic DNA fragment (-2865 -> 
+46) was cloned into the BglII site of the PGL3 basic vector. An 8XGTIIC-
luciferase construct (Addgene #34615) was used to assay TAZ transcriptional 
activity. Luciferase assays were performed using the Dual-Luciferase ® Reporter 
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Assay System (Promega). Cells were seeded in 24 well plates and transfected 
using 1.5ul Lipofectamine 3000, 1ul P3000, 800ng PGL3 and 200ng Renilla per 
well. Luciferase activity was measured at 24-36 hrs after transfection and all 
experiments were performed in triplicate. Promoter activity is reported as the 
average of the ratio of firefly to renilla luciferase. Two-tailed Student t-tests were 
used for statistical comparison. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
All experiments are mixed work by Cheng 
CHANG/Hira Lal Goel. 
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D is a mixed work by Cheng CHANG/Hira Lal Goel. 
E is by Cheng CHANG 
F-G are by Hira Lal Goel. 
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Figure 2.1. Laminin 511 is the preferred ligand for integrin α6Bβ1. A. 
Relative mRNA expression of LMα5, LMβ2, LMα3, LMβ3, LMβ1, LMγ2 in the 
MES and EPTH populations of CD44+/CD24- Src-transformed MCF10A cells and 
α6Aβ1- and α6Bβ1- expressing SUM1315 cells was quantified by qPCR. B. The 
expression of LMα5, LMγ2 and actin was assessed by immunoblotting in these 
cells. C. The cells described in A were assayed for their ability to adhere to 
collagen I, fibronectin, LM111 and LM511 (10µg/ml for top, 1 µg/ml for bottom). D 
(left). The ability of α6Bβ1-expressing SUM1315 cells to adhere within 30 
minutes to increasing concentrations of fibronectin, LM111 and LM511 was 
determined. D (right).  Control and α6B-depleted MDA-MB-231 cells were 
H is by Huijie Gao. 
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compared for their ability to adhere to increasing concentrations of LM111 and 
LM511.  α6B expression was depleted using TALENs as described (Goel et al. 
2014). E. LMα5 expression was diminished in the MES population of 
CD44+/CD24- Src-transformed MCF10A cells using shRNAs and the ability of 
these cells to adhere to glass was assayed.  F. Flow cytometric analysis of 
surface-bound LMα5 expression in EPTH and MES cells. G.  Three primary 
human breast tumors (T1, T2, T3) were dissociated and sorted by FACS using a 
LMα5 Ab. Cells with low surface-bound LMα5 (P1, P3, P5) were compared to 
cells with high surface-bound LMα5 (P2, P4, P6) for their ability to form 
mammospheres (bar graph). H. Frozen sections of human triple negative breast 
cancers were stained with a LMα5 Ab 4C7 using either immunohistochemistry 
(top) or immunofluorescence (bottom). Arrows depict individual cells with intense 
staining. Scale bar, 100uM. 
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Figure 2.2. Autocrine LM511 is necessary for self-renewal and tumor 
initiation. A. Mammosphere cultures of MES cells were treated with LMα5 
blocking antibodies (4C7 and 8G9) daily for 1 week and quantified. B. LMα5 
expression was diminished in α6Bβ1-expressing SUM1315 cells using shRNAs 
and these cells were used for serial passaging of mammospheres. C. Control 
(shGFP) and LMα5-diminished MES cells were injected into the mammary fat 
pads of NSG mice and tumor formation was assessed by palpation. The curve 
comparison was done using log rank test (p<0.05).  D. TBP mammary tumor 
cells were sorted by FACS using α6 and β1 integrin Abs.  The four populations 
generated were analyzed for α6B and LMα5 expression and mammosphere 
formation. Subsequently, LMα5 expression was diminished in the α6high/β1high 
population using shRNAs and the impact on mammosphere formation and tumor-
free survival (p<0.05) was determined.  E-F. LMα5 expression was diminished in 
All experiments are by Hira Lal Goel. 
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the α6high/β1high population using shRNAs and the impact on mammosphere 
formation (E) and tumor-free survival (F) (p<0.05) was determined.   
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A-B are mixed work by Cheng CHANG/Hira Lal 
Goel. C is by Cheng CHANG 
D is by Hira Lal Goel. 
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F is a mixed work by Cheng CHANG/Hira Lal Goel. 
E, G are by Cheng CHANG 
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H, I are mixed work by Cheng CHANG/Hira Lal 
Goel. J, K, L are by Hira Lal Goel. 
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Figure 2.3. LM511/α6Bβ1 promotes TAZ activation. A. Relative mRNA 
expression of TAZ target genes in the MES and EPTH populations of 
CD44+/CD24- Src-transformed MCF10A cells and α6Aβ1- and α6Bβ1-expressing 
SUM1315 cells was quantified by qPCR. B. α6Aβ1- and α6Bβ1-expressing 
SUM1315 cells were plated on a LM511 matrix and the localization of TAZ was 
assessed by immunofluorescence. C. Same assay in B was performed using the 
MES and EPTH populations of CD44+/CD24- Src-transformed MCF10A cells, 
and both YAP and TAZ localization was assessed. D. TEAD transcriptional 
activity was assayed in α6Aβ1- and α6Bβ1-expressing SUM1315 cells and 
parental cells by transient expression of the 8XGTIIC-luciferase reporter 
construct. E. TAZ expression was diminished using shRNA in the MES and 
α6Bβ1-expressing SUM1315 cells and the impact on serial mammosphere 
passage was evaluated. F. TAZ localization was assessed by 
immunofluorescence in confluent cultures of SUM1315 cells on either a LM111 
M is by Cheng CHANG. 
Chapter II                 60 
 
or LM5112 matrix.  G. Expression of TAZ target genes was quantified by qPCR 
in SUM1315 cells plated on either LM111 or LM511.  H-I. LMα5 expression was 
diminished in SUM1315 cells and the impact on the expression of TAZ 
localization (H) and TAZ target genes (I) was determined. J-K. Expression of 
integrin α6B was depleted in MDA-MB-231 cells using α6B-specific TALENS 
(see Fig. 2.1E).  These cells (Puro-alone, TALENs-pool, TALENS-C1 and 
TALENS-C2) were used to assay TEAD transcriptional activity (J) and 
expression of TAZ target genes (K).   L. Control (Puro-alone) and TALENs-pool 
cells were injected into the mammary fat pads of NSG mice and tumor formation 
was assessed by palpation. The curve comparison was done using log rank test 
(p<0.05).  M. Expression of LATS1/2 was diminished in EPTH cells using siRNAs 
and mRNA expression of LATS1/2 and LMα5 was quantified by qPCR. Bar 
graphs in this figure represent the average of three independent experiments and 
the p-value was determined using student t-test.  All scale bars, 100uM. 
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A, B are mixed work by Cheng CHANG/Hira Lal 
Goel. C, D are by Cheng CHANG. 
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E, F, G are by Hira Lal Goel. H is by Cheng CHANG. 
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Figure 2.4. TAZ regulates LMα5 expression. A. Expression of either TAZ or 
YAP was diminished in MES cells and the impact on LMα5 mRNA expression 
was quantified by qPCR.  LMα5 protein expression in TAZ-depleted cells was 
also evaluated by immunoblotting. B. TAZ expression was diminished in 
SUM1315 cells and the impact on LMα5 mRNA and protein expression was 
determined. C left. A luciferase construct containing the LMα5 promoter was 
generated and used to assay LMα5 transcriptional activity in the MES and EPTH 
cells. C right. LMα5 promoter activity was assayed using the same reporter 
construct in control and TAZ-expressing HEK293 cells. D. Schematic of the 
LMα5 promoter indicating location of the putative TEAD binding sites (top). 
Binding of TAZ to the LMα5 promoter was assayed by ChIP (bottom).  E-F.  
Cells with low surface-bound LMα5 (from PDX breast tumors) were isolated and 
infected with lentiviral particles expressing TAZ. Expression of TAZ and LMα5 
mRNA expression was quantified by qPCR (E). These transfected cells were 
also assayed for their ability to form mammospheres (F). G. Surface-bound LMα5 
was quantified by flow cytometry in the EPTH cells transfected with empty vector 
or TAZ shRNAs.  H. MES cells were cultured for 4 days, detached using EDTA 
(25 mM) and the exposed matrix was analyzed for LMα5 expression by 
immunofluorescence.  
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Supplementary Materials 
Table S2.1 Summary of RNA-seq of MES cells and EPTH cells (first 100 genes). 
Genes that are differentially expressed between the two populations are provided 
with statistical significance. Genes are sorted by their P-value. For complete list: 
http://genesdev.cshlp.org/content/suppl/2014/12/29/29.1.1.DC1/Table S1.xlsx 
Rank Gene 
length 
Epth 
(α6Aβ1+)-
RPKM 
Mes 
(α6Bβ1+)-
RPKM 
log2 Ratio 
Epth/Mes 
Up 
or 
Dn 
P-value FDR Symbol Description 
1 3390 0.7 47.0 6 09 Up 0.E+00 0.E+00 POSTN 
periostin, osteoblast specific 
factor 
2 3207 63.2 507.6 3 01 Up 0.E+00 0.E+00 SERPINE1 
serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 1 
3 3621 31.1 195.9 2.65 Up 0.E+00 0.E+00 AKR1C2 
aldo-keto reductase family 1, 
member C2 
4 8815 30.1 187.9 2.64 Up 0.E+00 0.E+00 FN1 fibronectin 1 
5 931 913.8 1939.4 1 09 Up 0.E+00 0.E+00 TIMP1 TIMP metallopeptidase inhibitor 1 
6 2151 621.9 1173.8 0 92 Up 0.E+00 0.E+00 VIM vimentin 
7 3740 431.3 808.2 0 91 Up 0.E+00 0.E+00 ANPEP 
alanyl (membrane) 
aminopeptidase 
8 5820 198.0 361.9 0 87 Up 0.E+00 0.E+00 THBS1 thrombospondin 1 
9 1245 2280.9 3957.8 0 80 Up 0.E+00 0.E+00 FTH1 ferritin, heavy polypeptide 1 
10 2947 67.1 190.3 1 50 Up 5.E-288 4.E-285 FBLN1 fibulin 1 
11 4291 53.2 137.8 1 37 Up 3.E-265 1.E-262 TXNRD1 thioredoxin reductase 1 
12 1815 50.5 192.2 1 93 Up 2.E-254 9.E-252 DKK1 
dickkopf 1 homolog (Xenopus 
laevis) 
13 889 767.5 1365.3 0 83 Up 6.E-242 3.E-239 FTL ferritin, light polypeptide 
14 3091 52.9 150.6 1 51 Up 7.E-241 4.E-238 COL8A1 collagen, type VIII, alpha 1 
15 4404 6.4 43.3 2.76 Up 1.E-214 5.E-212 S1PR3 
sphingosine-1-phosphate 
receptor 3 
16 2805 955.9 1279.1 0.42 Up 8.E-212 3.E-209 TGFBI 
transforming growth factor, beta-
induced, 68kDa 
17 2305 23.0 105.0 2.19 Up 1.E-208 4.E-206 DCN decorin 
18 5183 34.9 89.1 1 35 Up 6.E-203 2.E-200 ABCC3 
ATP-binding cassette, sub-family 
C (CFTR/MRP), member 3 
19 9445 1.2 14.4 3.63 Up 1.E-197 4.E-195 MAP2 microtubule-associated protein 2 
20 3670 34.1 98.3 1 53 Up 3.E-190 1.E-187 TIMP2 TIMP metallopeptidase inhibitor 2 
21 1416 185.6 404.7 1.12 Up 5.E-189 2.E-186 AKR1B1 
aldo-keto reductase family 1, 
member B1 (aldose reductase) 
22 3094 150.5 275.1 0 87 Up 5.E-184 2.E-181 EFEMP1 
EGF containing fibulin-like 
extracellular matrix protein 1 
23 8082 50.0 94.8 0 92 Up 2.E-183 5.E-181 SLC26A2 
solute carrier family 26 (sulfate 
transporter), member 2 
24 2674 26.7 93.6 1 81 Up 3.E-168 9.E-166 SERPINE2 
serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 2 
25 5365 35.5 82.8 1 22 Up 2.E-167 6.E-165 CUL4B cullin 4B 
26 6004 2.6 22.0 3 09 Up 4.E-167 1.E-164 MRC2 mannose receptor, C type 2 
27 11579 15.2 36.3 1 26 Up 4.E-166 1.E-163 COL12A1 collagen, type XII, alpha 1 
28 1251 37.5 161.3 2.10 Up 2.E-165 5.E-163 AKR1C3 
aldo-keto reductase family 1, 
member C3 
29 4743 35.5 85.9 1 27 Up 1.E-163 4.E-161 AXL AXL receptor tyrosine kinase 
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30 3698 2.8 31.0 3.49 Up 9.E-162 3.E-159 CADM3 cell adhesion molecule 3 
31 2358 15.2 74.2 2 29 Up 1.E-159 3.E-157 CTGF connective tissue growth factor 
32 4335 72.0 141.1 0 97 Up 6.E-159 2.E-156 ABLIM3 
actin binding LIM protein family, 
member 3 
33 8557 187.0 258.3 0.47 Up 1.E-158 3.E-156 FLNA filamin A, alpha 
34 2601 137.0 257.8 0 91 Up 5.E-157 1.E-154 NQO1 
NAD(P)H dehydrogenase, 
quinone 1 
35 11996 2.8 13.5 2 26 Up 7.E-146 2.E-143 MAP1B 
microtubule-associated protein 
1B 
36 18317 7.4 18.6 1 33 Up 9.E-146 2.E-143 AHNAK2 AHNAK nucleoprotein 2 
37 14905 1.6 9 0 2 53 Up 3.E-137 6.E-135 LRP1 
low density lipoprotein receptor-
related protein 1 
38 564 68.0 293.8 2.11 Up 8.E-137 2.E-134 S100A4 S100 calcium binding protein A4 
39 3840 21.2 62.0 1 55 Up 5.E-129 1.E-126 FSTL1 follistatin-like 1 
40 7384 107.8 160.6 0 57 Up 7.E-125 2.E-122 FKBP5 FK506 binding protein 5 
41 4578 9.7 36.9 1 93 Up 4.E-124 8.E-122 CCDC80 coiled-coil domain containing 80 
42 5349 83.5 137.4 0.72 Up 5.E-115 1.E-112 ASPH aspartate beta-hydroxylase 
43 2949 144.0 238.8 0.73 Up 3.E-113 5.E-111 ERGIC1 
endoplasmic reticulum-golgi 
intermediate compartment 
(ERGIC) 1 
44 1944 19.1 75.7 1 99 Up 5.E-113 1.E-110 ALDH3A1 
aldehyde dehydrogenase 3 
family, member A1 
45 4267 42.0 86.7 1 05 Up 1.E-109 2.E-107 ITGA5 
integrin, alpha 5 (fibronectin 
receptor, alpha polypeptide) 
46 3879 263.6 366.9 0.48 Up 4.E-107 7.E-105 ITGB1 
integrin, beta 1 (fibronectin 
receptor, beta polypeptide, 
antigen CD29 includes MDF2, 
MSK12) 
47 1384 19.6 88.6 2.18 Up 1.E-105 2.E-103 AKR1C1 
aldo-keto reductase family 1, 
member C1 
48 3327 3.5 26.4 2 91 Up 4.E-105 6.E-103 RTN1 reticulon 1 
49 5224 7.5 27.9 1 89 Up 1.E-104 2.E-102 KANK2 
KN motif and ankyrin repeat 
domains 2 
50 3806 4.8 27.0 2.49 Up 7.E-104 1.E-101 PRSS23 protease, serine, 23 
51 1270 13.0 77.5 2 58 Up 1.E-103 2.E-101 SRGN serglycin 
52 3434 2.4 22.7 3 23 Up 1.E-103 2.E-101 SLC44A2 
solute carrier family 44, member 
2 
53 3372 20.8 59.0 1 50 Up 2.E-103 4.E-101 FERMT2 fermitin family member 2 
54 4111 64.8 117.4 0 86 Up 1.E-102 2.E-100 ADAM9 
ADAM metallopeptidase domain 
9 
55 1847 71.1 158.3 1.15 Up 2.E-101 4.E-99 EPHX1 
epoxide hydrolase 1, microsomal 
(xenobiotic) 
56 6194 1.7 13.1 2 97 Up 1.E-99 2.E-97 WNT5A 
wingless-type MMTV integration 
site family, member 5A 
57 4072 60.3 110.3 0 87 Up 3.E-98 4.E-96 PLOD2 
procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 2 
58 11695 1.0 7 2 2 83 Up 2.E-97 3.E-95 FBN1 fibrillin 1 
59 6834 1.2 10.8 3.17 Up 6.E-96 9.E-94 SNED1 
sushi, nidogen and EGF-like 
domains 1 
60 7368 9.5 25.6 1.43 Up 1.E-91 2.E-89 ROS1 
c-ros oncogene 1 , receptor 
tyrosine kinase 
61 5817 13.5 34.6 1 36 Up 2.E-90 3.E-88 RPS6KA2 
ribosomal protein S6 kinase, 
90kDa, polypeptide 2 
62 15245 11.9 23.1 0 96 Up 4.E-90 6.E-88 HIPK2 
homeodomain interacting protein 
kinase 2 
63 5121 27.1 56.9 1 07 Up 6.E-90 9.E-88 SDC3 syndecan 3 
64 2246 1.6 24.4 3 97 Up 1.E-86 2.E-84 IGFBP4 
insulin-like growth factor binding 
protein 4 
65 4086 59.6 105.0 0 82 Up 2.E-84 3.E-82 NT5E 5'-nucleotidase, ecto (CD73) 
66 4488 0.2 9 3 5 85 Up 8.E-82 1.E-79 ABI3BP 
ABI family, member 3 (NESH) 
binding protein 
67 15249 95.8 122.3 0 35 Up 4.E-80 6.E-78 PLEC plectin 
68 2686 22.7 60.7 1.42 Up 2.E-78 2.E-76 BIN1 bridging integrator 1 
69 2295 33.5 81.8 1 29 Up 8.E-78 1.E-75 CYR61 cysteine-rich, angiogenic inducer, 
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61 
70 4841 2.5 14.8 2 56 Up 3.E-75 4.E-73 SPOCK1 
sparc/osteonectin, cwcv and 
kazal-like domains proteoglycan 
(testican) 1 
71 4949 10.3 29.0 1 50 Up 4.E-75 6.E-73 AOX1 aldehyde oxidase 1 
72 6264 33.9 59.7 0 82 Up 1.E-73 2.E-71 COL4A2 collagen, type IV, alpha 2 
73 5438 5.0 18.4 1 89 Up 1.E-72 1.E-70 MAOA monoamine oxidase A 
74 3047 49.3 94.6 0 94 Up 4.E-72 5.E-70 PLOD1 
procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 1 
75 1902 60.6 125.6 1 05 Up 8.E-72 9.E-70 BASP1 
brain abundant, membrane 
attached signal protein 1 
76 6821 22.3 42.5 0 93 Up 4.E-71 4.E-69 PXDN peroxidasin homolog (Drosophila) 
77 6427 123.7 167.6 0.44 Up 3.E-70 4.E-68 HDLBP 
high density lipoprotein binding 
protein 
78 850 107.2 237.1 1.15 Up 1.E-69 1.E-67 EMP3 epithelial membrane protein 3 
79 1150 293.0 458.7 0.65 Up 2.E-69 3.E-67 PTMS parathymosin 
80 586 820.2 1201.0 0 55 Up 2.E-69 3.E-67 LGALS1 
lectin, galactoside-binding, 
soluble, 1 
81 3002 4.5 23.4 2 39 Up 1.E-68 2.E-66 ANXA6 annexin A6 
82 2931 130.2 198.1 0.60 Up 8.E-68 9.E-66 SQSTM1 sequestosome 1 
83 5895 12.6 29.5 1 23 Up 3.E-67 4.E-65 NRP1 neuropilin 1 
84 13029 11.4 21.4 0 91 Up 3.E-66 3.E-64 NAV1 neuron navigator 1 
85 1624 343.3 485.0 0 50 Up 5.E-65 5.E-63 ANXA5 annexin A5 
86 7014 4.6 14.8 1.68 Up 5.E-64 5.E-62 IRS2 insulin receptor substrate 2 
87 5715 17.1 35.9 1 07 Up 1.E-63 1.E-61 CDC42EP3 
CDC42 effector protein (Rho 
GTPase binding) 3 
88 2040 107.0 180.5 0.75 Up 2.E-63 2.E-61 DUSP1 dual specificity phosphatase 1 
89 3254 10.9 33.0 1.60 Up 1.E-61 1.E-59 SYDE1 
synapse defective 1, Rho GTPase, 
homolog 1 (C. elegans) 
90 5817 14.2 31.1 1.13 Up 1.E-61 1.E-59 LAMB2 laminin, beta 2 (laminin S) 
91 5753 91.6 129.1 0 50 Up 7.E-61 7.E-59 TOP2A 
topoisomerase (DNA) II alpha 
170kDa 
92 2637 1.1 14.8 3 82 Up 3.E-60 3.E-58 FBLN5 fibulin 5 
93 2596 253.0 344.4 0.45 Up 4.E-60 4.E-58 P4HB 
prolyl 4-hydroxylase, beta 
polypeptide 
94 3927 21.4 46.1 1.11 Up 2.E-59 2.E-57 TFPI 
tissue factor pathway inhibitor 
(lipoprotein-associated 
coagulation inhibitor) 
95 2899 10.1 32.7 1.70 Up 2.E-59 2.E-57 ALDH3B1 
aldehyde dehydrogenase 3 
family, member B1 
96 2928 38.6 75.5 0 97 Up 3.E-58 3.E-56 MAGED1 melanoma antigen family D, 1 
97 3097 26.8 57.5 1.10 Up 5.E-58 5.E-56 PKN1 protein kinase N1 
98 4780 33.4 59.2 0 82 Up 4.E-57 4.E-55 SCARB2 
scavenger receptor class B, 
member 2 
99 7471 12.5 25.5 1 04 Up 2.E-56 2.E-54 CREB3L2 
cAMP responsive element binding 
protein 3-like 2 
100 8398 33.5 52.0 0.64 Up 4.E-56 4.E-54 ZBTB38 
zinc finger and BTB domain 
containing 38 
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Rank Gene 
length 
Epth 
(α6Aβ1+)
-RPKM 
Mes 
(α6Bβ1+)
-RPKM 
log2 
Ratio 
(Epth/
Mes) 
Up or 
Dn 
P-value FDR Symbol Description 
1 1075 281.5 22.5 -3.65 Down 0.E+00 0.E+00 S100A14 
S100 calcium binding protein 
A14 
2 5610 73.3 7.2 -3.36 Down 0.E+00 0.E+00 
COL17A
1 collagen, type XVII, alpha 1 
3 10511 75.6 9.5 -2.99 Down 0.E+00 0.E+00 LAMA3 laminin, alpha 3 
4 2831 147.1 18.9 -2.96 Down 0.E+00 0.E+00 MAL2 
mal, T-cell differentiation 
protein 2 (gene/pseudogene) 
5 1574 561.7 82.3 -2.77 Down 0.E+00 0.E+00 KRT17 keratin 17 
6 970 1437.6 235.6 -2.61 Down 0.E+00 0.E+00 S100A2 
S100 calcium binding protein 
A2 
7 1653 371.7 80.8 -2.20 Down 0.E+00 0.E+00 KRT14 keratin 14 
8 4543 791.8 252.9 -1.65 Down 0.E+00 0.E+00 SLC7A5 
solute carrier family 7 (amino 
acid transporter light chain, L 
system), member 5 
9 4482 152.3 49.0 -1.64 Down 0.E+00 0.E+00 SFRP1 
secreted frizzled-related 
protein 1 
10 5810 144.2 56.5 -1.35 Down 0.E+00 0.E+00 ITGA6 integrin, alpha 6 
11 5623 258.9 103.2 -1.33 Down 0.E+00 0.E+00 LAMC2 laminin, gamma 2 
12 2450 704.9 312.7 -1.17 Down 0.E+00 0.E+00 KRT6A keratin 6A 
13 2320 2161.9 1288.7 -0.75 Down 0.E+00 0.E+00 KRT5 keratin 5 
14 2331 2034.9 1415.9 -0.52 Down 0.E+00 0.E+00 HSPA8 heat shock 70kDa protein 8 
15 2871 117.7 26.6 -2.15 Down 2.E-292 1.E-289 
SERINC
2 serine incorporator 2 
16 2869 62.6 4.3 -3.85 Down 2.E-287 2.E-284 LAD1 ladinin 1 
17 5113 87.4 27.0 -1.70 Down 6.E-281 4.E-278 MYO1B myosin IB 
18 2350 278.7 112.6 -1.31 Down 1.E-278 9.E-276 SLC3A2 
solute carrier family 3 
(activators of dibasic and 
neutral amino acid transport), 
member 2 
19 4339 187.5 86.1 -1.12 Down 8.E-272 4.E-269 LAMB3 laminin, beta 3 
20 1336 358.6 120.7 -1.57 Down 3.E-269 2.E-266 SFN stratifin 
21 4043 42.4 4.9 -3.13 Down 3.E-228 1.E-225 CLCA2 chloride channel accessory 2 
22 9730 73.8 34.9 -1.08 Down 1.E-225 5.E-223 DSP desmoplakin 
23 4505 35.7 4.0 -3.17 Down 2.E-217 1.E-214 IRF6 interferon regulatory factor 6 
24 899 159.9 13.7 -3.54 Down 4.E-215 2.E-212 
MIR205H
G 
MIR205 host gene (non-protein 
coding) 
25 4815 24.9 1.2 -4.34 Down 7.E-210 3.E-207 CDH1 
cadherin 1, type 1, E-cadherin 
(epithelial) 
26 2767 93.9 25.6 -1.87 Down 2.E-188 7.E-186 EPGN epithelial mitogen 
27 466 9578.9 7565.1 -0.34 Down 2.E-179 7.E-177 MT2A metallothionein 2A 
28 4276 53.1 14.4 -1.88 Down 1.E-165 5.E-163 CDH3 
cadherin 3, type 1, P-cadherin 
(placental) 
29 2194 74.3 15.4 -2.27 Down 5.E-152 1.E-149 CD24 CD24 molecule 
30 5502 19.1 2.0 -3.24 Down 3.E-145 7.E-143 C1orf116 
chromosome 1 open reading 
frame 116 
31 5493 39.1 11.5 -1.76 Down 2.E-143 6.E-141 PVRL1 
poliovirus receptor-related 1 
(herpesvirus entry mediator C) 
32 3037 96.3 35.9 -1.42 Down 6.E-143 2.E-140 TRIM29 tripartite motif containing 29 
33 5561 19.8 2.7 -2.88 Down 2.E-135 5.E-133 DSG3 desmoglein 3 
34 2943 31.5 3.1 -3.33 Down 4.E-132 1.E-129 IL1A interleukin 1, alpha 
35 2716 954.8 737.4 -0.37 Down 4.E-124 1.E-121 
HSP90A
B1 
heat shock protein 90kDa 
alpha (cytosolic), class B 
member 1 
36 14565 5.2 0.4 -3.72 Down 1.E-119 2.E-117 FAT2 
FAT tumor suppressor 
homolog 2 (Drosophila) 
37 7733 33.7 13.4 -1.33 Down 3.E-115 6.E-113 PTPRF 
protein tyrosine phosphatase, 
receptor type, F 
38 2871 26.2 2.2 -3.58 Down 2.E-114 4.E-112 MPZL2 myelin protein zero-like 2 
39 1485 394.2 224.8 -0.81 Down 3.E-114 6.E-112 KRT18 keratin 18 
40 2379 207.9 112.0 -0.89 Down 6.E-114 1.E-111 MYC 
v-myc myelocytomatosis viral 
oncogene homolog (avian) 
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41 3309 98.2 44.3 -1.15 Down 9.E-114 2.E-111 SDC1 syndecan 1 
42 3319 48.2 13.7 -1.81 Down 1.E-111 3.E-109 ST14 
suppression of tumorigenicity 
14 (colon carcinoma) 
43 6531 13.6 1.8 -2.90 Down 1.E-110 2.E-108 CCND2 cyclin D2 
44 3009 33.8 5.9 -2.52 Down 2.E-108 4.E-106 
ERVME
R34-1 
endogenous retrovirus group 
MER34, member 1 
45 6978 18.5 4.5 -2.05 Down 4.E-106 7.E-104 DSC3 desmocollin 3 
46 5496 41.0 15.8 -1.38 Down 2.E-105 4.E-103 TIMP3 
TIMP metallopeptidase 
inhibitor 3 
47 1787 285.8 163.5 -0.81 Down 5.E-99 9.E-97 PTGES prostaglandin E synthase 
48 2867 166.4 94.8 -0.81 Down 7.E-94 1.E-91 
SLC43A
3 
solute carrier family 43, 
member 3 
49 2397 609.1 450.7 -0.43 Down 1.E-93 2.E-91 HDGF 
hepatoma-derived growth 
factor 
50 5717 10.8 1.0 -3.48 Down 9.E-92 1.E-89 XDH xanthine dehydrogenase 
51 2048 146.5 71.7 -1.03 Down 1.E-88 2.E-86 CREG1 
cellular repressor of E1A-
stimulated genes 1 
52 3510 26.0 5.3 -2.30 Down 8.E-88 1.E-85 
ALDH1A
3 
aldehyde dehydrogenase 1 
family, member A3 
53 3887 811.1 668.8 -0.28 Down 2.E-87 2.E-85 
HSP90A
A1 
heat shock protein 90kDa 
alpha (cytosolic), class A 
member 1 
54 598 250.4 84.2 -1.57 Down 1.E-85 2.E-83 SLPI 
secretory leukocyte peptidase 
inhibitor 
55 2292 38.0 7.5 -2.34 Down 3.E-85 4.E-83 LSR 
lipolysis stimulated lipoprotein 
receptor 
56 1449 1796.0 1455.8 -0.30 Down 7.E-85 9.E-83 NPM1 
nucleophosmin (nucleolar 
phosphoprotein B23, numatrin) 
57 3806 15.0 1.4 -3.47 Down 1.E-84 1.E-82 ESRP1 
epithelial splicing regulatory 
protein 1 
58 1715 40.3 5.9 -2.76 Down 5.E-82 7.E-80 CD82 CD82 molecule 
59 4927 10.3 0.8 -3.74 Down 2.E-80 3.E-78 TP63 tumor protein p63 
60 986 797.3 545.2 -0.55 Down 2.E-77 2.E-75 GSTP1 glutathione S-transferase pi 1 
61 838 82.7 14.0 -2.56 Down 8.E-76 1.E-73 CSTA cystatin A (stefin A) 
62 2375 213.2 132.3 -0.69 Down 4.E-75 5.E-73 AHCY adenosylhomocysteinase 
63 1731 30.2 3.3 -3.17 Down 1.E-71 1.E-69 EPCAM 
epithelial cell adhesion 
molecule 
64 1369 109.4 41.8 -1.39 Down 3.E-71 4.E-69 FGFBP1 
fibroblast growth factor binding 
protein 1 
65 4839 170.2 119.6 -0.51 Down 3.E-71 4.E-69 DDX21 
DEAD (Asp-Glu-Ala-Asp) box 
helicase 21 
66 4928 15.4 3.3 -2.22 Down 9.E-70 1.E-67 INPP5D 
inositol polyphosphate-5-
phosphatase, 145kDa 
67 2220 58.7 20.9 -1.49 Down 3.E-69 4.E-67 GJB3 
gap junction protein, beta 3, 
31kDa 
68 586 126.7 27.3 -2.21 Down 3.E-68 3.E-66 S100A9 
S100 calcium binding protein 
A9 
69 1085 686.1 476.6 -0.53 Down 3.E-68 4.E-66 S100A16 
S100 calcium binding protein 
A16 
70 5544 72.1 43.1 -0.74 Down 6.E-68 7.E-66 CYCS cytochrome c, somatic 
71 2845 61.1 27.0 -1.18 Down 1.E-64 1.E-62 PKP3 plakophilin 3 
72 1621 39.2 9.4 -2.05 Down 1.E-63 1.E-61 DMKN dermokine 
73 678 63.0 5.8 -3.45 Down 1.E-63 1.E-61 SAA1 serum amyloid A1 
74 5503 12.3 2.6 -2.23 Down 4.E-63 4.E-61 FAM84B 
family with sequence similarity 
84, member B 
75 11436 11.0 4.1 -1.44 Down 4.E-63 4.E-61 MYO10 myosin X 
76 1394 38.4 5.8 -2.73 Down 4.E-63 4.E-61 SOX15 
SRY (sex determining region 
Y)-box 15 
77 1817 123.9 62.2 -0.99 Down 5.E-63 5.E-61 SPINT2 
serine peptidase inhibitor, 
Kunitz type, 2 
78 2376 28.0 5.9 -2.25 Down 2.E-62 2.E-60 SH2D3A SH2 domain containing 3A 
79 778 19.6 0.5 -5.36 Down 2.E-62 2.E-60 FXYD3 
FXYD domain containing ion 
transport regulator 3 
80 361 2838.9 2122.9 -0.42 Down 4.E-62 4.E-60 RPS27 ribosomal protein S27 
81 11733 19.5 9.9 -0.97 Down 7.E-62 7.E-60 CDK6 cyclin-dependent kinase 6 
82 2323 1176.7 990.5 -0.25 Down 1.E-61 1.E-59 LDHA lactate dehydrogenase A 
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83 2478 139.6 82.5 -0.76 Down 3.E-61 3.E-59 CNN2 calponin 2 
84 4188 18.3 4.7 -1.97 Down 6.E-61 6.E-59 SLC1A3 
solute carrier family 1 (glial 
high affinity glutamate 
transporter), member 3 
85 2252 32.1 7.8 -2.04 Down 6.E-60 6.E-58 TINAGL1 
tubulointerstitial nephritis 
an igen-like 1 
86 18103 27.0 17.6 -0.62 Down 7.E-60 6.E-58 DST dystonin 
87 1270 395.3 260.3 -0.60 Down 4.E-59 3.E-57 AREG amphiregulin 
88 4090 302.6 234.4 -0.37 Down 5.E-59 5.E-57 TNS4 tensin 4 
89 3715 18.6 4.5 -2.06 Down 5.E-58 4.E-56 
LEPREL
1 leprecan-like 1 
90 595 1087.9 760.1 -0.52 Down 7.E-58 6.E-56 S100A11 
S100 calcium binding protein 
A11 
91 2269 415.3 312.1 -0.41 Down 2.E-55 1.E-53 CCT3 
chaperonin containing TCP1, 
subunit 3 (gamma) 
92 2873 130.1 81.3 -0.68 Down 2.E-54 1.E-52 SLC1A5 
solute carrier family 1 (neutral 
amino acid transporter), 
member 5 
93 9112 5.2 0.8 -2.66 Down 3.E-54 2.E-52 ABCA12 
ATP-binding cassette, sub-
family A (ABC1), member 12 
94 5616 65.3 40.8 -0.68 Down 2.E-53 2.E-51 EGFR 
epidermal growth factor 
receptor 
95 5182 19.4 7.0 -1.48 Down 2.E-53 2.E-51 MYO1D myosin ID 
96 4225 15.2 3.7 -2.03 Down 5.E-53 4.E-51 C1orf106 
chromosome 1 open reading 
frame 106 
97 4830 35.1 16.9 -1.05 Down 1.E-52 8.E-51 F11R F11 receptor 
98 4326 14.8 3.6 -2.02 Down 1.E-52 1.E-50 TGFA 
transforming growth factor, 
alpha 
99 4319 71.2 42.6 -0.74 Down 3.E-52 3.E-50 PERP PERP, TP53 apoptosis effector 
100 2732 562.3 455.4 -0.30 Down 3.E-51 2.E-49 NCL nucleolin 
 
 
 
 
 
 
 
 
 
 
 
 
Rna-Seq is by Cheng CHANG. 
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Table S2.2: Sequences of the qPCR primers used in the study. 
Realtime Primers FW RW 
ANKRD1 AGTAGAGGAACTGGTCACGG  TGTTTCTCGCTTTTCCACTGTT 
BMP4 AAAGTCGCCGAGATTCAGGG GACGGCACTCTTGCTAGGC 
CTGF AAAAGTGCATCCGTACTCCCA CCGTCGGTACATACTCCACAG 
CYR61 CTCGCCTTAGTCGTCACCC  CGCCGAAGTTGCATTCCAG 
GAPDH ATCATCCCTGCCTCTACTGG GTCAGGTCCACCACTGACAC 
LMα3 TGCTCAACTACCGTTCTGCC TCCAGTTCTTTTGCGCTTTGT 
LMα5 GACTGCCAACAGTGCCAAC CCACCCTGATAGGTGCCAT 
LMβ1 AGGAACCCGAGTTCAGCTAC  CACGTCGAGGTCACCGAAAG 
LMβ2 CCTGGGAACTTCGACTGGG  AAGCACTTCTTTTCGTCCTGC 
LMβ3 CCAAAGGTGCGACTGCAATG AGTTCTTGCCTTCGGTGTGG 
LMγ2 GACAAACTGGTAATGGATTCCGC  TTCTCTGTGCCGGTAAAAGCC 
TAZ (WWTR1) TCCCAGCCAAATCTCGTGATG AGCGCATTGGGCATACTCAT 
UBC GGAGCCGAGTGACACCATTG CAGGGTACGACCATCTTCCAG 
YAP1 TAGCCCTGCGTAGCCAGTTA TCATGCTTAGTCCACTGTCTGT 
α6A (TapMan) Cat. Mm01327571_m1 XS (Life Technologies)   
α6B (TapMan) Cat. Mm01333831_m1 XS (Life Technologies)   
GAPDH(TaqMan) Cat. Mm99999915_g1 (Life Technologies)   
      
ChIP qPCR primers FW RW 
1 ACGACTCACGGCTGAGTCAGAT AGTGGCAGCCCGAGAGAAGT 
2 AAGCAGTGAGCCCGGTGATT CACTTTAAGCCTCCTAGCGGC 
3 GCCGAGAGAGCTGGTGGAGT AAATACTCTCAGATAGGGAAATAGGGG 
4 GATTATGTACTCGTGGTCCCTGAGA GCTGATGAAGTCATAGGATTTATCCA 
5 ACCTCCCAGGAGCTACACTGC CGGTCACCTGCAACTGCAA 
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Fig. S2.1 Supplementary evidence for LM511/ α6Bβ1 regulating CSCs through 
TAZ. A. α6A- or α6B-expressing SUM1315 cells were compared for their ability 
to adhere to increasing concentrations of LM111 and LM511. B. Control and 
α6B-depleted MDA-MB-231 (TALENs) cells were compared for their ability to 
adhere to LM511 (5 µg/ml) in the presence of either control rat IgG or GoH3. C-D. 
Expression of vimentin and E-cadherin mRNA was quantified by qPCR in cells 
A-D are by Hira Lal Goel, E is a mixed work by 
Cheng CHANG/Hira Lal Goel. 
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isolated from fresh breast tumors expressing either high or low levels of surface-
bound LMα5. E. TEAD transcriptional activity was assayed in EPTH and MES 
cells by transient expression of the 8XGTIIC luciferase reporter construct. 
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Chapter III 
Id2 Complexes with the SNAG Domain of Snai1 Inhibiting Snai1-Mediated 
Repression of Integrin β4 
This chapter represents work previously published and presented in accordance 
with copyright law: 
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Chapter III                 74 
 
Abstract 
The Epithelial-Mesenchymal Transition (EMT) is a fundamental process that 
underlies development and cancer. Although the EMT involves alterations in the 
expression of specific integrins that mediate stable adhesion to the basement 
membrane such as α6β4, the mechanisms involved are poorly understood. Here, 
we report that Snai1 inhibits β4 transcription by increasing repressive histone 
modification (H3K27Me3). Surprisingly, Snai1 is expressed and localized in the 
nucleus in epithelial cells, but it does not repress β4. We resolved this paradox 
by discovering that Id2 complexes with the SNAG domain of Snai1 on the β4 
promoter and constrains the repressive function of Snai1. Disruption of the 
complex by depleting Id2 resulted in Snai1-mediated β4 repression with a 
concomitant increase in H3K27Me3 modification on the β4 promoter. These 
findings establish a novel function for Id2 in regulating Snai1 that has significant 
implications for the regulation of epithelial gene expression.  
 
Introduction 
The regulated expression of specific integrins is a fundamental component of 
development, tissue homeostasis and many diseases (Hynes 2002). A prime 
example of this concept is the regulation of epithelial integrins, which function 
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primarily in the anchoring of epithelial cells to laminins in the basement 
membrane (Yurchenco 2011). Developmental and pathological processes that 
necessitate epithelial cell migration often involve disruption of the stable adhesive 
contacts provided by integrins (Stepp et al. 1996; Lipscomb and Mercurio 2005; 
Margadant and Sonnenberg 2010). The two major integrins that anchor epithelial 
cells to basement membrane laminins are α3β1 and α6β4 (Stepp et al. 1990; Lee 
et al. 1992; DiPersio et al. 1997; Watt 2002), and stimuli that disrupt epithelial 
adhesion frequently target the expression, localization and cytoskeletal 
interactions of α6β4 (Stepp et al. 1996; Rabinovitz and Mercurio 1997; 
Rabinovitz et al. 1999; Mercurio et al. 2001; Margadant and Sonnenberg 2010). 
The epithelial-mesenchymal transition (EMT) provides a useful model system for 
studying the regulation of epithelial integrins. Although studies on the EMT have 
focused largely on mechanisms that disrupt cell-cell adhesions (Yang and 
Weinberg 2008; Thiery et al. 2009), disruption of integrin-mediated anchoring to 
matrix is an important component of the EMT but the mechanisms involved are 
poorly understood.  
The EMT of normal mammary epithelial cells involves transcriptional 
repression of the β4 integrin subunit (referred as ‘β4’), which results in loss of the 
α6β4 integrin (Yang et al. 2009). This repression is associated with a decrease in 
active histone modifications (H3K9Ac and H3K4Me3) and an increase in 
repressive histone modification (H3K27Me3) on the β4 promoter (Yang et al. 
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2009). Although these previous observations provide a foundation for 
understanding how β4 is regulated during the EMT, much is not known about the 
mechanisms involved. For example, are specific transcription factors involved in 
β4 repression and, if so, what is their relationship to epigenetic modifications? 
Our pursuit of this problem in the current study revealed a key role for the zinc 
finger protein Snai1 in repressing β4. Interestingly, however, we observed that 
Snai1 is expressed in the nucleus of mammary epithelial cells but it does not 
repress β4 transcription. This observation is consistent with other reports of 
Snai1 expression in epithelial cells (Vincent et al. 2009; Putzke et al. 2011; Celia-
Terrassa et al. 2012). Aside from the possibility that Snai1can be excluded from 
the nucleus (Zhou et al. 2004), it is not known why nuclear Snai1 does not 
repress genes in epithelial cells. In an attempt to understand this paradox, we 
discovered that Snai1 interacts with Id2 and demonstrate that Id2 constrains the 
repressive function of Snai1 by binding to its SNAG domain, a key domain for 
recruiting co-repressors including H3K27 methyltransferase (Herranz et al. 2008). 
Id2 is a helix-loop-helix protein family member that has been implicated as an 
antagonist of the EMT (Kondo et al. 2004; Kowanetz et al. 2004). Specifically, the 
EMT in several epithelial models is associated with strong suppression of Id2, 
and forced Id2 expression in mesenchymal cells is able to partially rescue an 
epithelial phenotype (Kowanetz et al. 2004). Given that Id2 can also impede the 
ability of Snai1 to repress E-cadherin, these findings provide insight into the 
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regulation of epithelial genes and they identify a novel mechanism for how Id2 
maintains epithelial differentiation. 
 
Results  
Snai1 represses integrin β4 transcription: The normal murine mammary gland 
cell line (NMuMG) undergoes a bona fide EMT in response to TGF-β, and 
subsequent TGF-β withdrawal results in a mesenchymal-epithelial transition 
(MET) (Gal et al. 2008; Yang et al. 2009). To screen for potential factors that 
could repress β4 transcription, we compared the gene expression profiles of 
epithelial NMuMG cells (EPTH), TGF-β treated NMuMG cells (EMT), and TGF-β 
treated/TGF-β withdrawn NMuMG cells (MET) (Fig. S3.1A). Among the potential 
EMT-promoting transcription factors, only Snai1 exhibited a significant induction 
during EMT and reduction during MET (GEO accession: GSE48204). 
Given that Snai1 can repress several epithelial genes including E-cadherin 
(Batlle et al. 2000; Cano et al. 2000; Guaita et al. 2002; Vega et al. 2004; Vincent 
et al. 2009), we assessed whether it could repress β4. For this purpose, we used 
an inducible system in which a human Snai1 cDNA was fused with an estrogen 
receptor (ER) construct (Mani et al. 2008). This Snai1-ER construct was stably 
expressed in NMuMG cells, enabling Snai1 function to be activated in the 
presence of 4-hydroxytamoxifen (4-OHT). Activation of Snai1 activity repressed 
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β4 protein and mRNA expression significantly (Fig. 3.1A, B). Note that 4-OHT 
itself had minimal effect on β4 expression and transcription in control cells. 
Expression of a mouse Snai1 cDNA in NMuMG cells also repressed β4 
expression and transcription (Fig. 3.1C, D, and E). Snai1 also repressed E-
cadherin expression (Fig. 3.1C), consistent with previous data (Batlle et al. 2000; 
Cano et al. 2000). Conversely, we diminished Snai1 expression using two 
independent shRNAs (Fig. 3.1F) and observed a rescue of β4 protein (Fig. 3.1G) 
and mRNA expression (Fig. 3.1H) in TGF-β-treated cells. Taken together, these 
data indicate that Snai1 represses β4 and is responsible for the loss of β4 during 
TGF-β-induced EMT. 
Snai1 induces repressive histone mark H3K27Me3 on β4 promoter: Snai1 is 
known to modify the histone marks on the promoter of its target genes, including 
demethylation of H3K4 (Lin et al. 2010b), deacetylation of H3/H4 (Peinado et al. 
2004), as well as methylation of H3K27 (Herranz et al. 2008), H3K9 (Dong et al. 
2012a; Dong et al. 2012b) and H4R3 (Hou et al. 2008). We chose to focus on the 
Polycomb complex-associated repressive mark, H3K27Me3, as a proof of 
principle for the function of Snai1, because our earlier study established that the 
increase of this mark is concomitant with the repression of β4 (Yang et al. 2009). 
Indeed, ectopic expression of Snai1 significantly increased the H3K27Me3 
histone modification, but not H3K9Me3 (Fig. S1B), on the β4 promoter, as 
evidenced by chromatin immunoprecipitation (ChIP) (Fig. 3.2A, left).This 
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approach also demonstrated that Snai1 binds specifically to an E-box that is 
located shortly after the transcription start site of the β4 promoter, designated E5 
(Fig. 3.2A, right). Note that E5 is the only E-box in the β4 promoter that is 
conserved across species (Fig. S1C). 
Snai1 is not functional in epithelial NMuMG cells: We detected Snai1 expression 
in epithelial NMuMG cells (Fig. 3.2B), and found that it is localized in the nucleus 
(Fig. 3.2C, D). This observation prompted us to use ChIP to assess the binding 
pattern of endogenous Snai1 on the β4 promoter in epithelial cells and compare 
it to EMT cells.  Snai1 binds to the E5 in both epithelial and EMT cells (Fig. 3.2E). 
However, it does not repress β4 in epithelial NMuMG cells (Fig. 3.2B). Based on 
this observation, we speculated that an adaptor protein may impede the function 
of Snai1. Id2 captured our attention for several reasons. Our microarray analysis 
revealed that it is the most repressed gene during the EMT (GSE48204). 
Moreover, Id2 localized in both the nucleus and cytoplasm of epithelial cells (Fig. 
3.2C) and its expression is depleted during the EMT (Fig. 3.2F, G). Id1 
expression is also diminished during the EMT (Fig. 3.2G) but it has been 
reported to facilitate the EMT (Cheung et al. 2011; Cubillo et al. 2013). 
Interestingly, Id3 expression increases during the EMT (Fig. 3.2G). 
Id2 and Snai1 form a complex: Although Id2 can interact with Rb and bHLH 
proteins (Benezra et al. 1990; Iavarone et al. 1994; Norton 2000), there is no 
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evidence that it can complex with zinc finger proteins. To test the possibility that 
Snai1 partners with Id2, we performed co-immunoprecipitation assays, and found 
that Id2 co-immunopurifies with Snai1 in vitro (Fig. 3.3A) and in vivo (Fig. 3.3B). 
Moreover, GST-pull down assays using Id2 as bait confirmed that this interaction 
is direct (Fig. 3.3C). These biochemical interactions were substantiated by the 
observation that Id2 and Snai1 co-localize in puncture structure within the nuclei 
of epithelial NMuMG cells (Fig. 3.3D). Furthermore, ChIP experiments revealed 
that Id2 binds to the same locus (E5) of the β4 promoter as Snai1 does, and the 
binding is lost during the EMT (Fig. 3.3E). Importantly, knock-down of Snai1 
diminished this specific enrichment of Id2 on the β4 promoter (Fig. 3.3F, G). 
Given that Id2 cannot bind DNA directly (Norton 2000), these results indicate that 
a Snai1-Id2 complex binds to the β4 promoter in epithelial NMuMG cells. 
Loss of Id2 diminishes β4 and E-cadherin expression: The finding that Id2 
complexes with Snai1 in epithelial cells and that Snai1 does not repress β4 
expression in these cells suggested that Id2 compromises the repressive function 
of Snai1. To disrupt this complex, we depleted Id2 by two independent shRNAs 
in epithelial cells and assessed β4 expression. Silencing Id2 resulted in 
decreased β4 mRNA and protein expression compared to control cells (Fig. 3.4A, 
B). Importantly, knock-down of Snai1 in the Id2-silenced cells completely rescued 
the expression of β4 mRNA and protein, indicating that the repression of β4 that 
occurs in response to Id2 loss is Snai1-dependent (Fig. 3.4C, D). Similar results 
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were obtained for E-cadherin, an established target of Snai1 (Fig. 3.4A, C, D). 
Taken together, these data reveal that Id2 restrains Snai1 from its ability to 
repress epithelial genes.   
Id2 masks the SNAG domain of Snai1 and prevents the H3K27Me3 repressive 
mark: The SNAG domain is crucial for the repressive function of Snai1 because it 
mediates the interaction of Snai1 with many co-repressors (Peinado et al. 2004; 
Herranz et al. 2008; Lin et al. 2010b; Dong et al. 2012a). This finding is 
consistent with our data that deletion of this domain abrogated the ability of Snai1 
to repress β4 expression (Fig. 3.5A). Moreover, a ∆SNAG mutant of Snai1 
functions as a dominant negative mutant that rescues β4 expression in NMuMG 
cells engineered to express Snai1 (Fig. 3.5B). Given the importance of this 
domain and our observation that Id2 inhibits the function of Snai1 via a complex 
formation, the possibility emerged that the Id2-Snai1 interaction is mediated 
through the SNAG domain of Snai1. Indeed, HA-Snai1 co-immunopurified with 
Id2, but the HA-∆SNAG mutant failed to do so (Fig. 3.5C), demonstrating that 
SNAG is essential for the Id2-Snai1 interaction. Moreover, we confirmed that the 
SNAG domain itself is sufficient to bind Id2 directly using a GST-pull down 
approach, in which the GST-SNAG domain fusion protein was used as bait for 
Id2 (Fig. 3.5D). Considering that Id1 is also repressed by the EMT (Fig. 2G), we 
also examined the potential interaction between Id1 and Snai1. Although Id1 and 
Snai1 can interact, the interaction is 4-6 fold weaker than the interaction between 
Chapter III                 82 
 
Id2 and Snai1 (Fig. 3.5C, D). This finding indicates that that Id2 is dominant 
interacting partner of Snai1 when both Id1 and Id2 are expressed. 
Our data indicate that Id2 can mask the SNAG domain, which should 
result in the failure of Snai1 to establish H3K27Me3. Indeed, knockdown of Id2 in 
epithelial NMuMG cells caused a significant elevation of this repressive histone 
mark (Fig. 3.5E). We also assessed whether Id2-Snai1-mediated regulation of β4 
occurs in other epithelial cells. Specifically, MCF7 cells are well-differentiated 
carcinoma cells that express β4, Id2 and Snai1 (Fig. 3.5F, G). Importantly, 
endogenous Snai1 is localized in the nucleus of these cells (Fig. 3.5F) and 
knock-down of Id2 caused a reduction of β4 expression (Fig. 3.5G). 
 
Discussion 
A major conclusion of our study is that Snai1 can be expressed in the nucleus of 
epithelial cells and bound to specific promoters but its ability to repress 
transcription is restrained by its association with Id2 (Fig. 3.6). More specifically, 
we demonstrate that the repressive function of Snai1 is compromised by the 
interaction of its SNAG domain with Id2. To our knowledge, this is the first 
identification of a functional antagonist that binds the SNAG domain of Snai1 in 
the epithelial cells. In previous studies, the SNAG domain was shown to be 
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essential for recruiting several cooperative co-factors that are necessary for 
removing active histone marks and adding repressive ones, including Suz12 
(Herranz et al. 2008), Suv39H1 (Dong et al. 2012a), LSD1 (Lin et al. 2010b), 
HDAC1/2 (Peinado et al. 2004) and Ezh2 (Tong et al. 2012). Based on our 
observation that the repressive mark H3K27Me3, but not H3K9Me3, is elevated 
in response to Id2 loss, it is possible that the co-repressor responsible for 
H3K27Me3, Ezh2, is unable to bind Snai1 in the presence of Id2.  We pursued 
this possibility experimentally, but the data generated did not enable a definitive 
conclusion. 
The ability of Id2 to complex with the zinc finger protein Snai1 provides a 
novel mechanism accounting for the role of Id2 in the EMT. It is known that Id2 is 
repressed dramatically in epithelial cells by TGF-β signaling and that forced 
expression of Id2 rescues epithelial gene expression in TGF-β-treated cells 
(Kowanetz et al. 2004). The ability of Id2 to bind and sequester E2A, a basic-
helix-loop-helix protein, from binding target genes including E-cadherin has been 
proposed as a mechanism to account for these observations (Kondo et al. 2004). 
Our finding that Id2 complexes with Snai1 on the promoter of target gene and 
prevents Snai1 from recruiting transcriptional co-repressors provides a distinct 
mechanism for how Id2 contributes to epithelial differentiation. Collectively, the 
existing data substantiate the potency of Snai1 in promoting a mesenchymal 
transition and its need to be regulated. Our finding that Id1 can also interact with 
Chapter III                 84 
 
Snai1 suggests that this interaction may involve the HLH domain.  Given that the 
interaction with Id2 is much stronger, however, Id2-specific domains may also be 
involved. 
The data reported here expand and complement other studies on the 
repression of β4 and other epithelial genes. Snail has a preeminent role in the 
repression of β4 (Fig. 1) and E-cadherin (Cano et al. 2000), but several other 
factors contribute to this repression including Twist, Slug and Zeb1 (Thiery et al. 
2009). For example, based on the findings that Zeb1 represses β4 transcription 
(Drake et al. 2010) and that Snai1 induces Zeb1 expression (Dave et al. 2011), 
we infer that β4 transcriptional repression involves a cascade of Snai1 and Zeb1-
mediated events and that Id2 functions upstream to prevent the initiation of this 
cascade by complexing with the SNAG domain of Snai1. This hypothesis is 
supported by the observation that Id2 overexpression in TGF-β-treated epithelial 
cells suppressed Zeb1 induction (Shirakihara et al. 2007). In a different direction, 
we reported that β4 repression during the EMT is associated with promoter 
methylation (Yang et al. 2009) and it is known that Snai1 can mediate DNA 
methylation (Dong et al. 2012b). Although these observations suggest that 
methylation of the β4 promoter should increase in response to Id2 loss, we did 
not detect such an increase (not shown). Most likely, this observation indicates 
that additional factors are required for de novo methylation such as DNMT3s 
(Cedar and Bergman 2009). 
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The mechanistic relationship between Id2 and β4 is foreshadowed by 
other studies that support our central hypothesis. Of note, the progenitor 
population of lung epithelial cells is enriched in both Id2 and β4 expression 
(Rawlins et al. 2009; McQualter et al. 2010) suggesting that Id2 may facilitate the 
purported role of β4 in the function of lung epithelial stem cells (Chapman et al. 
2011). Our data may also have significant implications for the regulation of β4 in 
cancer.  For example, nuclear Id2 expression correlates significantly with a poor 
prognosis in non-small cell lung carcinoma (Rollin et al. 2009), and β4 expression 
is also up-regulated in these carcinomas (Boelens et al. 2007). Clearly, Id2-
mediated regulation of β4 expression merits further investigation, especially in 
the context of metastasis, which involves a reversion to an epithelial phenotype 
and increased expression of β4 (Falcioni et al. 1986). 
 
Materials and Methods 
Cell culture: NMuMG cells were purchased from ATCC and maintained in 
complete medium that contains DMEM (high glucose) medium containing 10% 
fetal bovine serum, 10 µg/ml insulin, 100ug/ml streptomycin and 100 units/ml 
penicillin at 37ºC incubator supplied with 5% CO2. TGF-β (Peprotech) was added 
directly into the culture mediumat a final concentration of 4ng/ml for the time 
periods indicated in the figure legends. For long-term (more than 2 days) 
Chapter III                 86 
 
treatment with TGF-β (EMT), cells were passed into fresh complete medium 
containing 4 ng/ml TGF-β. For the TGF-β withdrawal experiments, cells that had 
undergone EMT in the presence of TGF-β were passed into fresh complete 
medium without TGF-β. MCF7 cells were purchased from ATCC and maintained 
in the DMEM (low glucose) medium containing 10% fetal bovine serum,100ug/ml 
streptomycin and 100 units/ml penicillin at 37ºC incubator supplied with 5% CO2. 
Microarray analysis: The QIAGEN RNeasy mini-kit was used to extract total RNA 
from untreated epithelial NMuMG cells (EPTH), NMuMG cells treated with TGF-β 
for 11 days (EMT) and NMuMG cells treated with TGF-β for 11 days followed by 
TGF-β withdrawal for 13 days (MET). For each sample, 500ng of total RNA with 
PolyA-RNA control stock was used to synthesize the biotin-labeled antisense 
RNA (aRNA), following the protocol described in the manual of Affymetrix3’ IVT 
Express Kit. The aRNA was then purified using aRNA binding magnetic beads 
and fragmented to a size range of 90-110nts. The purified aRNA (15ug) was 
used to hybridize with Mouse Genome 430 2.0 Array (Affymetrix). All samples 
were run induplicate. Analyses were performed using BRB-ArrayTools developed 
by Dr. Richard Simon and BRB-ArrayTools Development Team (Simon et al. 
2007).The raw array data were normalized using the RMA algorithm. The three 
sample groups described above were subject to class comparison, and genes 
that were differentially expressed are summarized in the Venn diagram shown in 
Fig. S1A. Genes that exhibited less than 2-fold change or a P value>0.001 were 
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excluded from the data summary presented. The microarray data has been 
deposited into GEO database and the accession number is: GSE48204. 
Biochemical techniques: For quantitative, real-time PCR (qPCR), total RNA was 
extracted using the Trizol reagent (Invitrogen), and cDNAs were produced using 
Superscript II (Invitrogen) according to the manufacturer’s instructions. qPCR 
was performed using a SYBR green master mix (Applied Biosystems). The 
qPCR primers used are provided in Table S3.1. Two-tailed Student t-tests were 
used for statistical comparison. Immunoblotting was performed as described 
previously (Shaw et al. 1997) using the following antibodies: β4(505) (Rabinovitz 
et al. 1999), actin (A20660, Sigma), E-cadherin (334000; Invitrogen), Id2 (C-20, 
Santa Cruz), Id1 (C-20, Santa Cruz), Snai1 (L70G2, Cell Signaling), Pol2 
(8WG16, Covance), Flag (M2, Sigma)and HA (Clone 3F10, Roche). 
Densitometry of the immunoblots was performed using Gel-pro Analyzer V4.0.  
The nuclear fraction assay used is described in the Abcam protocol 
database (http://www.abcam.com/index.html?pageconfig=resource&rid=11408). 
Briefly, cells were extracted using buffer A (10 mM HEPES, 1.5 mM MgCl2, 10 
mMKCl, 0.5 mM DTT, 0.05% NP40, pH 7.9), and span 800 g at 4° for 10 min. 
The supernatant from this extract was saved as the cytoplasmic fraction. The 
remaining pellets were dounce homogenized, extracted using buffer B (5 mM 
HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 26% glycerol (v/v), pH 7.9) 
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containing 300mM NaCl and centrifuged at 16.1k g for 20 min at 4°C.  The 
supernatant from this extraction was saved as the nuclear fraction. 
For the co-immunoprecipitation (IP) experiments, cell extracts were prepared 
using NP-40 or Triton lysis buffers (Boston BioProduct) containing protease 
inhibitor cocktail (Roche). Extracts were precleared using a 50% protein G 
suspension (Biovision). For each IP, 200-500 µg of total protein was incubated 
with 40 µl of anti-Flag (M2) bead slurry (Sigma) at 4 °C overnight in the 
appropriate lysis buffer. In some experiments, total protein was incubated with 
1µg antibody overnight at 4 °C first and then subject to beads-enrichment by 40µl 
of 50% protein G slurry (Biovision) for another 1-2 hrs at 4 °C. Subsequently, 
beads were washed with 1 ml cold IP lysis buffer, and immunoprecipitated 
fractions were extracted by boiling in 2X SDS-loading Buffer (Boston Bioproducts). 
Samples were then resolved by SDS-PAGE and immunoblotted. IP antibodies are: 
Snai1 Ab1 (L70G2, Cell Signaling), Snai1 Ab2 (G-7, Santa Cruz) and HA (Clone 
3F10, Roche). 
Constructs, transfections and RNA interference: pCMX-based expression 
constructs including HA alone, HA-Snai1 (mus) or Flag-Id2 (mus) were inserted 
between the KpnI-BamHI sites of the pCMX vector. PT7CFE1 based expression 
construct, PT7CFE1-Id2 and PT7CFE-Id1 (mus), were cloned between NdeI and 
NotI sites of the PT7CFE1-CHis vector (Thermo Fisher Scientific).To construct 
the luciferase reporter for the β4 promoter, promoter fragments from -1572 to 
Chapter III                 89 
 
+254 were amplified by PCR using KOD high-fidelity DNA polymerase kit 
(Novagen). Each fragment was gel-purified by QIAGEN gel extraction kit, 
digested with restriction enzymes (NEB) and inserted between NheI-HindIII into 
the pGL3-basic vector (Promega). All constructs were confirmed by sequencing 
analysis (Genewiz).  
Retroviral-mediated expression in NMuMG cells was performed using the 
MSCV-IRES-GFP vector (Addgene, Plasmid 9044, also termed pMIG) and stable 
expression was confirmed by assessing GFP positive cells, which comprised 90-
100% of the cell population. Full length Snai1 (mus) ORF (open reading frame) 
was PCR amplified from the total cDNA of NMuMG cells, and ligated into pMIG. 
To construct Snai1-∆SNAG, Snai1 (mus) ORF lacking the 4th-60thnucleotides 
was generated by PCR and ligated into pMIG. An HA tag was added on the 3’ 
end of Snai1 or Snai1-∆SNAG ORF to produce Snai1-HA or Snai1-∆SNAG-HA. 
All cDNAs were inserted between XhoI-NotI sites of pMIG. 
To construct GST-SNAG and GST-Snai1, the SNAG domain (No.1-60nts of 
mus Snai1) or full length Snai1 (mus) ORF was cloned into the EcoRI site of the 
PGEX4T-1 vector (GE healthcare). For GST-Id2, full length Id2 ORF was PCR 
amplified and then cloned into pGEX-4T-1 vector with BamH1/Sal1 restriction 
sites. All constructs were confirmed by sequencing analysis (Genewiz). 
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The inducible system using ER-fusion protein has been described previously 
(Danielian et al. 1993; Littlewood et al. 1995; Metzger et al. 1995). The retroviral 
Snai1-ER expression construct, PWZL-Snai1-ER (referred to as “Snail-ER”), was 
providedby Karl Simin (UMMS). The construction of the vector is described 
elsewhere (Mani et al. 2008). NMuMG cells infected by Snai1-ER virus were 
selected by blasticidin (6µg/ml) for 7 days. All of the blasticidin-resistant NMuMG 
cells with Snai1-ER stable integration were then treated with medium containing 
250nM 4-hydroxytamoxifen (4-OHT) for Snai1 activation or equal volume of 
ethanol (the solvent of 4-OHT) as control for 7 days prior to protein analysis. 
The ShSnai1 expression constructs were generated using Psuperior-Neo 
retroviral vector (Oligoengine). The ShRNA targetingsequences are: 
GGGAGAAAGATGTTTACAT (ShSnai1-2), CACCTTCTTTGAGGTACAA 
(ShSnai1-3). Stable expression of these ShRNAs in the NMuMG cells was 
obtained by G418 (1mg/ml) selection for 7 days after retroviral infection, using 
ShGFP as a non-targeting control. The Mus and Homo ShId2 expression 
constructs used in this study were purchased from Open Biosystems and the 
reference numbers are: Mus: ShId2-1: TRCN0000054390 and ShId-2: 
TRCN0000054391. Homo: ShId2-1: TRCN0000021064 andShId2-
2:TRCN0000021065. Stable expression of these Plko based vectors in NMuMG 
cells was obtained by puromycin (2µg/ml) selection for 5-6 days, using ShGFP as 
a non-targeting control. 
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Chromatin Immunoprecipitation (ChIP): ChIP assays were performed using 
ChIP-it express Kit (Active motif, cat# 53008) with minor modifications according 
to Tian et al.(Tian et al. 2012). Cells were first cross-linked with 2mM 
dissuccinimidyl glutarate (cat# c1104, Proteochem) for 45min at RT, and then 
washed and subject to crosslinking by 1% formaldehyde (Sigma) for 15 min at 
RT. The reaction was quenched using 125mM Glycine for 5 min. Subsequently, 
the cells were washed by PBS and scraped from the plate and lyzed in 1ml of 
lysis buffer (5mM PIPES pH8.0, 85mM KCl, 0.5% NP-40 and protease inhibitor). 
Nuclear pellets were lyzed again with nuclear fraction buffer (50mM Tris-HCl, 
10mM EDTA, 1% SDS, pH8.0 and protease inhibitor) and resuspended in 400 µl 
of ChIP buffer (150mM NaCl, 50mM Tris-HCl, 1mM EDTA, 1% TritonX-100, 0.1% 
Sodium Deoxycholate, 0.1%SDS with protease inhibitor). Chromatin was then 
subject to sonication using Sonicator 3000 (Misonix, Inc.) for 4 cycles of 20 
second (Power=2.0) bursts to generate chromatin fragments that ranged 200-700 
bps. The sonicated chromatin samples were then used in the ChIP assay 
following the protocol of the Kit. Each ChIP sample contains chromatin from 1-
2*106 cells, and 2µg of Ab (ChIP antibodies: H3K27Me3, 07-449, Millipore; 
H3K4Me3, 05-1339, Millipore; H3K9Me3, 07-442, Millipore; H3, 2650, Cell 
signaling; Snai1 ChIP grade Ab was a kind gift generated by Dr. de Herreros 
(Franci et al. 2006); Id2 Clone C-20, Santa Cruz.) or isogenic IgG were used. 
ChIP incubation was performed overnight (15 hrs-16.5 hrs) at 4ºC. The 
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immunoprecipitated DNA was then subjected to realtime PCR analysis using 
ChIP primers targeting different regions of β4 promoter. Primer sets for ChIP 
PCR on the β4 promoter are provided in Table S3.1. Two-tailed Student t-tests 
were used for statistical comparison. 
Immunofluorescence microscopy: Immunofluorescence microscopy was 
performed as described previously (Rabinovitz and Mercurio 1997) using Snai1 
Ab (1:50 dilution; L70G2, Cell Signaling) and Id2 Ab (1:200 dilution, C-20, Santa 
cruz), anti-mouse TRITC secondary Ab (1:250 dilution; 15-025-150, Jackson 
Immuno) and anti-rabbit FITC secondary Ab (1:250 dilution; 711-096-152, 
Jackson Immuno). The microscope is made by ZEISS, with the model LSM-700 
and the pictures were taken using the camera of Axio Imager Z2, at room 
temperature (23ºC). The parameters for objective lense are 40X, Oil, with 
numerical aperture of 1.30. The pictures were analyzed and exported using ZEN 
2011, and processed using Adobe Photoshop.  
Luciferase reporter assays: NMuMG cells were grown in 24-well plates and 
transiently transfected with 0.5µg of each reporter construct and 0.1µg of Renilla 
using 2µl of Lipofectamine 2000 in 100 µl of Opti-MEM mix for each well. 
Luciferase assay were performed using the Dual-Luciferase® Reporter Assay 
System (Promega). All experiments were performed in triplicate. Promoter 
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activity was reported as the average of the ratio of firefly luciferase to renilla 
luciferase. Two-tailed Student t-tests were used for statistical comparison. 
GST-pull down experiments: The methods for GST purification and the GST pull-
down assay have been described elsewhere (Einarson et al. 2007). Briefly, GST 
constructs were expressed in E.coli strains JM109 or BL21 (DE3) with IPTG 
(100µM) stimulation for 3hrs at 37ºC. Cells were then lyzed, and the GST-fusion 
proteins were purified using glutathione sephorase 4B (Bioworld). The molecular 
mass of the purified GST-fusion protein was confirmed by SDS-PAGE. In vitro 
translation of Id1, Id2 and Snai1 was performed using “1-Step Human In Vitro 
Protein Expression Kit” (Thermo Fisher Scientific). The translated lysates were 
then pre-cleared using 5µl of 50% suspension of GST-beads prior to GST pull-
down. Equal amounts of the GST-fusion protein-beads suspension were mixed 
with the in vitro translated lysates in the lysis buffer (20mM Tris-HCl, pH 8.0, 
200mM NaCl, 1mM EDTA, 0.5% NP40 and protease inhibitor) with a total volume 
of 500µl. After 2 hours of incubation at 4 °C, the beads were washed 4 times with 
1ml cold lysis buffer. Samples were resolved by SDS-PAGE and subjected to 
radioautography or immunoblotting. 10-12% of in vitro translated lysates were 
used as input. 
 
 
Chapter III                 94 
 
Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All experiments are by Cheng CHANG 
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FIG. 3.1. Snai1 represses β4 integrin. A: NMuMG cells that stably express 
either a control ER construct or a Snai1-ER construct were treated with either 
250nM 4-OHT or an equal volume of ethanol (solvent) for 7 days. Subsequently, 
expression of β4, E-cadherin and actin was assessed by immunoblotting. 
Numbers below the blots indicate relative intensity of the bands based on 
densitometry. B: Expression of β4 and E-cadherin mRNA was quantified in the 
same populations as in A.* P<0.05. C-E: Snai1 cDNA or empty vector was 
expressed in NMuMG cells and the expression of β4, E-cadherin, Snai1 and 
actin was evaluated by immunoblotting (C), and β4 mRNA expression was 
quantified by qPCR (D); * P<0.05. The relative luciferase activity of the β4 
promoter in the control and Snai1-expressing cells was determined (E); * P<0.05. 
F: Snai1 expression in NMuMG cells was stably diminished using two 
independent shRNAs and the effect was quantified by qPCR. G: The control and 
Snai1 knock-down cells described in F were treated with either carrier (EPTH) or 
TGF-β (EMT) for 2 days to induce an EMT, and the expression of β4, Snai1 and 
actin was assessed by immunoblotting (G). H: The expression of β4 mRNA in the 
control or ShSnai1 NMuMg cells with the same treatment as in G was quantified 
by qPCR; * P<0.05.  
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FIG. 3.2. Nuclear Snai1 binds β4 promoter in epithelial cells. A: NMuMG cells 
expressing Snai1 were generated and the H3K27Me3 modification on β4 
promoter was assessed using ChIP followed by qPCR (left); Snai1 binding on the 
β4 promoter in Snai1-expressing NMuMG cells was also assessed by ChIP 
followed by qPCR (right); *P<0.05. The enrichment of the antibody was 
normalized to H3 (H3K27Me3) or IgG (Snai1). Lower: Schematic of β4 promoter 
All experiments are by Cheng CHANG 
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and the regions targeted by ChIP primers are indicated. B: NMuMG cells were 
treated with 4ng/ml TGF-β (EMT) or Vehicle (EPTH) for 2 days to induce an EMT 
and the expression of β4, E-cadherin, actin and Snai1 was assessed by 
immunoblotting. C: Total cell extracts, as well as the cytoplasmic and nuclear 
fractions of epithelial NMuMG cells were obtained. The expression of Snai1, Id2, 
Pol2 (positive control for the nucleus/ negative control for cytoplasm), and actin 
was assessed by immunoblotting. D: The localization of Snai1 in control (EPTH) 
and TGF-β-treated (EMT) NMuMG cells was assessed by immunofluorescence 
microscopy.Bar, 10um. E: Snai1 binding on the β4 promoter in control (EPTH) 
and TGF-β-treated (EMT) NMuMG cells was determined by ChIP and qPCR 
(right); *P<0.05. F: Extracts of Control (EPTH) and TGF-β-treated (EMT) NMuMG 
cells were obtained, and the expression of Id2 and actin was assessed by 
immunoblotting. G: NMuMG cells were treated with 4ng/ml TGF-β (EMT) or 
vehicle (EPTH) for 3 days to induce an EMT and then TGF-β was withdrawn for 
another 6 days to trigger an MET. Expression of β4, E-cadherin, Snai1, Id1, Id2 
and Id3 mRNA was assessed by qPCR. 
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B is performed by Cheng CHANG; A-C is performed 
by Xiaofang YANG 
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FIG. 3.3. Id2 and Snai1 form a complex. A: NMuMG cells were transiently co-
transfected with pCMX-Flag-Id2 and pCMX-HA-Snai1/pCMX-HA for 72 hours. 
Cell extracts were immunoprecipitated using anti-Flag beads and then 
immunoblotted using an HA Ab. 10% input was used as loading control. B: 
NMuMG extracts were immunoprecipitated using Snai1 Ab1 or Ab2 and blotted 
with Snai1 Ab1 and Id2. Total cell extract (10%) was run as a positive control 
(Input). Note that the band of Snai1 in the IgG control is non-specific, which has a 
slight size shift. C: GST and GST-Id2 were expressed in E.coli and purified using 
glutathione sepharose beads. A fraction of the purified proteins was resolved by 
SDS-PAGE to verify the correct molecular mass of the target proteins (left). 
Subsequently, the in vitro transcribed/translated radioactive (S35) Snai1 protein 
was subject to GST-pull down by GST or GST-Id2 and the retained fraction or 10% 
input was resolved by SDS-PAGE and detected by radioautography (right). D: 
The localization of Snai1 and Id2 in NMuMG cells was assessed by 
immunofluorescence using confocal microscopy. Bar, 10um. Arrowheads 
indicate sites of co-localization. E-F: Id2 binding on the β4 promoter in control 
(EPTH) and TGF-β-treated (EMT) NMuMG cells (E), or in control and Snai1-
depleted epithelial NMuMG cells (F) was assessed by ChIP followed by qPCR; 
*P<0.05. G: The efficiency of Snai1 depletion was assessed by immunoblotting 
(G). 
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FIG. 3.4. Repression of β4 as a consequence of Id2-loss is Snai1-dependent. 
A: The expression of Id2 in NMuMG cells was diminished using two independent 
shRNAs and the expression of β4, E-cadherin, Id2 and actin was examined by 
immunoblotting. B: β4 mRNA expression in the cells described in A was 
quantified by qPCR; *P<0.05. C: The expression of β4, E-cadherin, actin, Snai1 
and Id2 was evaluated by immunoblotting in NMuMG cells that had been 
depleted of Id2, or both Id2 and Snai1, using shRNAs, and compared to the 
appropriate shGFP control cells. D: Expression of β4 (left) and E-cadherin (right) 
mRNA expression in the cells described in C was quantified by qPCR; *P<0.05.  
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FIG. 3.5. Id2 inhibits Snai1 by interacting with its SNAG domain. A: NMuMG 
cells stably expressing either Snai1 or Snai1-∆SNAGwere generated and the 
expression of β4, actin and Snai1 was assessed by immunoblotting. B: Ectopic 
expression of Snai1-∆SNAG or vector in cells stably expressing Snai1 was 
achieved by virus transduction. Subsequently, the expression of β4, Actin and 
Snai1 was assessed by immunoblotting (left). β4 mRNA expression in the same 
populations was quantified by qPCR (right); *P<0.05. C: Snai1-HA or Snai1-
∆SNAG-HA (referred as ∆SNAG-HA) was expressed in NMuMG cells, and 
extracts were immunoprecipitated using an HA antibody. The retained proteins 
were resolved by SDS-PAGE and subject to immunoblotting. 10% input was 
used for each IP as a loading control. D: GST, GST-SNAG and GST-Snai1 
constructs were expressed in E. coli and purified using glutathione-sepharose 
beads. A fraction of the purified protein was resolved by SDS-PAGE to verify the 
molecular mass of the target proteins (upper). Subsequently, the in vitro 
transcribed/translated Id2 or Id1 protein was subject to GST-pull down with either 
GST, GST-SNAG or GST-Snai1 (as indicated in the figure) and the retained 
fraction or 12.5% of the input was resolved by SDS-PAGE and detected by 
immunoblotting (bottom). Numbers indicate the percentage of the pulled-down 
fraction relative to 100% input as determined by densitometry. E. H3K27Me3 
modification on the β4 promoter in the Id2-depleted NMuMG cells was assessed 
by ChIP followed by qPCR; *P<0.05. F: MCF7 cells were fractionated as in Fig. 
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2C, and the expression of Id2, β4, Snai1 and Pol2 was assessed by 
immunoblotting. G: Id2 expression was depleted in MCF7 cells using two 
independent shRNAs, and the expression of β4, actin and Id2 in these cells, as 
well as control cells, was assessed by immunoblotting. 
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FIG. 3.6. Proposed model for how Id2 regulates Snail-mediated repression 
of integrin β4.  Id2 complexes with the SNAG domain of Snai1 bound to the β4 
promoter in epithelial cells, and it impairs the ability of Snai1 to increase the tri-
methylation of H3K27, a repressive histone modification. The loss of Id2 that 
occurs as a consequence of the EMT enables putative co-repressors to increase 
H3K27me3 and repress β4 transcription. 
 
 
 
 
 
Figure is made by Cheng CHANG 
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Supplementary Materials 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.1. Analysis of gene expression as a function of EMT and analysis 
of the β4 promoter. A: NMuMG cells were treated with 4ng/ml TGF-β for 11 
days to induce an EMT; and these cells were subject to EMT withdrawl for 
another 13 days to induce an MET. mRNA profiles from untreated (EPTH), EMT 
A: Xiaofang generated the data and Cheng CHANG 
made the data analysis; other 
experiments/analysis are by Cheng CHANG 
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and MET cells were analyzed by microarray. The Venn diagram of the number of 
genes that are downregulated (left) or upregulated (right) in the EMT were shown. 
B: Chromatins were collected in NMuMG cells stably expressing empty vector 
(Vector) or Snai1. The H3K9Me3 modification on the β4 promoter was then 
assessed by ChIP followed by qPCR. *P<0.05. C: The multiple-alignments of 
genomic DNA sequences surrounding the E5 locus were shown. The figure is 
generated using UCSC genome browser. 
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Table S3.1 shows the sequences of the primers used in this study. 
Realtime PCR Forward Reverse 
Id1 5'-CCTAGCTGTTCGCTGAAGGC-3' 5'-CTCCGACAGACCAAGTACCAC-3' 
Id2 5'-ATGAAAGCCTTCAGTCCGGTG-3' 5'-AGCAGACTCATCGGGTCGT-3' 
Id3 5'-CTGTCGGAACGTAGCCTGG-3' 5'-GTGGTTCATGTCGTCCAAGAG-3' 
Snai1 5'-CACACGCTGCCTTGTGTCT-3' 5'-GGTCAGCAAAAGCACGGTT-3' 
18s 5'-GTCGCTCGCTCCTCTCCTACT-3' 5'-TCTGATAAATGCACGCATCCC-3' 
β4 5'-GCAGACGAAGTTCCGACAG-3' 5'-GGCCACCTTCAGTTCATGGA-3' 
E-cadherin 5'-CAGGTCTCCTCATGGCTTTGC-3' 5'-CTTCCGAAAAGAAGGCTGTCC-3' 
GAPDH 5'-AGGTCGGTGTGAACGGATTTG-3' 5'-TGTAGACCATGTAGTTGAGGTCA-3' 
   
ChIP PCR 
  
 
Forward Reverse 
Con* 5'-CCTGCCGCAAGAGTAAGATTT-3' 5'-AACCGATAGGCAAGGACTGG-3' 
E5* 5'-CAGCTCCTGCCCCGACA-3' 5'-GAGCCAGCAGCGCTTTATG-3' 
E5 adjacent* 5'-GCCCAAGTCCGAGGTAGTCT-3' 5'-GGCAGGGTTGGCACCTGT-3' 
Neg 5'-CAGAGGTTACGGCAGTTTGTCT -3' 5'-GGGCGAATCTATAAAGGGCGT -3' 
* These primers 
require 2% DMSO 
in the realtime 
reaction. 
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Chapter IV 
General Discussion 
Overview 
This thesis has focused on two α6 integrins: α6β1 and α6β4. The first chapter 
revealed how α6β1 regulates breast cancer stem cells. Specifically, I showed 
that the α6Bβ1 splice variant induces CSC properties by engaging laminin, 
LM511. Also, I found that LM511 is necessary for CSC maintenance and that it 
can be used as a surface marker to identify breast CSCs. Importantly, I 
discovered that α6Bβ1-LM511 signaling promotes the activation of the Hippo 
transducer TAZ in breast CSCs. Moreover, I also found the LMα5, the key 
subunit of LM511, is a transcriptional target of TAZ. Although TAZ has been 
shown to sustain breast CSCs, the mechanisms involved are not known. Here I 
provide one mechanism that involves the ability of TAZ to regulate the formation 
of a LM511 matrix that enables α6Bβ1 signaling. 
In the second study, I have established that the EMT transcription factor, 
Snai1, represses β4 transcription by establishing the PRC2-associated repressive 
histone mark, H3K27Me3. However, I also discovered that this repression is 
regulated by Id2. The presence of nuclear Id2 can block the repressive function 
of Snai1 on β4, thus permitting the active transcription of this integrin. This 
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finding provides an important mechanism for how Snai1 function is regulated; i.e., 
by Id2 interacting with the SNAG domain of Snai1. In contrast, the previous work 
on Snai1 concluded that its activity is regulated by either its expression level or 
its intracellular localization. My work also unveiled a novel mechanism for the 
transcriptional regulation of β4 by Id2 and Snai1. 
 
CSC Niche 
After the discovery and characterization of CSCs, the concept of the “CSC niche” 
has been proposed (Borovski et al. 2011; Cabarcas et al. 2011; Lu et al. 2012). 
CSC niche is a special microenvironment that maintains and protects CSCs, and 
some studies also reported that the CSC niche is able to generate CSC-like cells 
from non-tumorigenic cells (Jordan et al. 2006; Visvader and Lindeman 2008; 
Visvader and Lindeman 2012). Known components of the CSC niche include 
tumor vasculature, oxygen availability, stromal cells (CAFs and immune cells), 
growth factors, cytokines and ECM (Visvader and Lindeman 2008; Borovski et al. 
2011; Cabarcas et al. 2011; Visvader and Lindeman 2012). 
Surprisingly, little is known about the ECM in the context of the breast 
CSC niche. My work has shown that a specific ECM protein, LM511, regulates 
breast CSC properties. Also, a small population (2%) of breast cancer cells in 
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tumors exhibits surface-bound LMα5 and has stem cell properties (Chang et al. 
2015). In embryonic stem (ES) cell studies, LM511 is found in the inner cell mass 
of blastocysts (a natural origin of the ES cells), and it sustains the 
undifferentiated state of human ES cells for more than 20 passages 
(Domogatskaya et al. 2008; Rodin et al. 2010; Spenle et al. 2013). In contrast, 
LM111 and LM332 induce the differentiation of ES cells (Domogatskaya et al. 
2008). However, no one has ever examined the contribution of this laminin to 
CSCs. Clearly, my data demonstrated that LM511 is an essential component for 
the CSC niche by its specific ligation with the α6Bβ1 integrin that is preferentially 
expressed by the CSCs. I also demonstrated that CSCs synthesize and secrete 
LMα5, generating a LM511 matrix that involves TAZ. Interestingly, there is 
evidence that the ability of tumor cells to secrete certain laminin subunits 
correlates with the shift from a poorly metastatic phenotype to a highly metastatic 
phenotype of breast cancer (Naba et al. 2014). Indeed, high grade breast 
carcinomas secrete more LMα5 than do low grade breast carcinomas (Chia et al. 
2007), and breast cancer cells with metastatic potential secrete abundant LMα5 
(Zhou et al. 2014). These observations are correlated with the fact that 
aggressive breast cancer cells have more CSCs (Chaffer et al. 2013). To this 
end, it will be important to identify whether these metastatic breast cells that are 
associated with high LMα5 expression also express the α6B splice variant, which 
activates the ‘LM511-α6Bβ1-TAZ-LMα5’ axis that promote breast CSCs. 
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Another ECM component linked with the CSC niche is collagen I (Col I). It 
has been shown that the Col I promotes stem-like phenotypes in colorectal 
carcinomas via the α2β1 integrin (Kirkland 2009). Besides ECM, other factors of 
the CSC niche have been discovered. It has been shown that in skin tumors and 
glioblastoma (GBM), the CSC population is associated with vascular endothelial 
cells in a ‘perivascular niche’ (Calabrese et al. 2007; Charles et al. 2010; Beck et 
al. 2011). These perivascular niches (PVNs) contain factors that maintain CSCs. 
For example, the PVN in the GBM has high levels of NO (nitric oxide), which 
activates the stem cell pathway, Notch (Charles et al. 2010). In other studies, 
however, researchers also found that a hypoxic environment is essential to 
maintain CSCs in some GBM and other cancers (Li et al. 2009; Borovski et al. 
2011; Cabarcas et al. 2011). Hypoxia activates the transcription factors Hif1α and 
Hif2α (Hif, hypoxia inducible factor). Hif2α promotes the transcription of the 
VEGF and the stem cell factor Oct4 in the CSC population of GBM (Li et al. 
2009). Also, Hif1α can increase the protein stability of the EMT inducer Snai1 
(Vinas-Castells et al. 2010). Both the perivascular niche and the hypoxic niche of 
CSCs involve VEGF. On one hand, VEGF promotes growth and survival signals 
in the endothelial cells via PI3K and the mTOR pathway and it stimulates 
angiogenesis (Borovski et al. 2011). On the other hand, studies from our lab and 
others demonstrated autocrine VEGF signaling maintains CSCs by its co-
receptors Nrp1 or Nrp2, depending on the context (Beck et al. 2011; Goel et al. 
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2013). Importantly, VEGF signaling has been shown to induce the α6B splice 
variant (Goel et al. 2014), thus my study in chapter II has also established a 
novel mechanism that how VEGF maintains the CSC niche. 
Furthermore, growth factors other than VEGF that promote the EMT have 
been found to be components of the CSC niche. For example, the Weinberg 
group discovered that paracrine and autocrine signaling, maintains the stem cell 
state of both normal and cancerous breast cells by TGF-β and Wnt signaling 
pathway (canonical and non-canonical) activation (Scheel et al. 2011). These 
pathways cooperatively disrupt the homeostatic state of breast epithelial cells 
and promote the EMT program that generates CSC properties (Scheel et al. 
2011). My data also implicated the involvement of the Wnt activation, along with 
TAZ activation, in the α6B cells, as discussed in following paragraphs. 
 
The Hippo Pathway and its Transducers TAZ and YAP 
My study has identified a novel outside-in signaling by the α6Bβ1 integrin through 
engaging LM511: the activation of the transcription events by the hippo 
transducer TAZ, as described below. 
The canonical Hippo pathway: The canonical hippo pathway is a kinase cascade, 
which functions to inhibit TAZ and YAP. When this pathway is activated, the 
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upstream kinases, Mst1/2 (its ortholog in fly is termed Hippo), are phosphorylated 
(Zhao et al. 2008a). Phosphorylated Mst complexes with WW45 and then they 
are able to phosphorylate LATS1/2 and Mob (Zhao et al. 2008a). Upon 
phosphorylation, LATS1/2 forms a complex with Mob and ultimately 
phosphorylates TAZ and YAP on specific serine residues (Zhao et al. 2008a; 
Zhao et al. 2010). This final step of serine phosphorylation induces the 
cytoplasmic retention of TAZ and YAP, which inhibits their activity because of 
their sequestration from the nucleus (Zhao et al. 2010). Cell polarity and contact 
inhibition have been shown to activate the hippo pathway (Zhao et al. 2007; 
Boggiano and Fehon 2012). When the hippo pathway is inhibited, TAZ and YAP 
are stabilized and translocated into the nucleus as transcription cofactors (co-
activators in many cases) (Moroishi et al. 2015). They bind to transcription 
factors (TFs) to activate target genes that were originally found to control tissue 
growth (Camargo et al. 2007; Moroishi et al. 2015). One of the TFs they bind are 
TEAD family members (TEAD1-4) (Zhao et al. 2008b; Moroishi et al. 2015).  
Intriguingly, unlike other growth factor mediated signaling pathways, which 
have surface receptors to respond to specific extracellular stimuli, the hippo 
pathway does not have a specific surface receptor to trigger its signaling. As a 
result, studies have been trying to define factors that contribute to the ‘On’ and 
‘Off’ states of the hippo pathway and the respective repression and activation of 
TAZ and YAP (Piccolo et al. 2014; Moroishi et al. 2015). To date, several protein 
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factors have been shown to regulate TAZ and YAP through regulation of the 
canonical hippo pathway. The first factor is Merlin. Merlin, encoded by NF2, 
localizes in proximal to tight junctions and adherens (Piccolo et al. 2014; Moroishi 
et al. 2015). It functions as an upstream activator of Mst1/2 and LATS1/2 and it 
negatively regulates YAP and TAZ (Piccolo et al. 2014; Moroishi et al. 2015). The 
second factor is angiomotin (AMOT). AMOT proteins can bind either F-actin or 
YAP, and these interactions are mutually exclusive (Mana-Capelli et al. 2014). 
The association of AMOT with F-actin enables YAP to go into the nucleus (Mana-
Capelli et al. 2014). In contrast, the AMOT-YAP association keeps YAP in the 
cytoplasm and renders it inactive (Mana-Capelli et al. 2014). AMOT proteins also 
activate LATS2 and promote LATS2-mediated YAP inhibition (Paramasivam et al. 
2011). Moreover, LATS2, in turn, can phosphorylate AMOT proteins to prevent 
them binding to actin, which results in the inhibitory effect of YAP by AMOTs 
(Mana-Capelli et al. 2014). The third factor is the GPCR (G protein coupled 
receptor). GPCR proteins are seven transmembrane receptors that are 
regulators of the Rho GTPases, which can positively or negatively (less 
frequently) regulate YAP and TAZ in a LATS1/2-dependent fashion (Yu et al. 
2012a). The fourth factor is Scribble. Scribble is a membrane-bound protein that 
is involved in maintaining the basolateral polarity of the cells (Zhan et al. 2008), 
and it complexes with Mst1/2 as well as LATS1/2 and activates the hippo 
pathway (Cordenonsi et al. 2011). Delocalization of Scribble by polarity-
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disrupting events including EMT inhibits the hippo pathway and activates TAZ 
and YAP (Cordenonsi et al. 2011). Moreover, loss of LKB1, an upstream kinase 
of MAPK1, which stabilizes the Scribble/hippo kinases complex, also activates 
YAP and TAZ (Mohseni et al. 2014). The fifth factor is Crumb. The crumb 
complex (Crumb3/PATJ/PALS/AMOT) determines the apical/lateral polarity of 
epithelial cells (Varelas et al. 2010). It has been shown that the crumb complex 
directly interacts with TAZ and YAP and promotes their phosphorylation and 
cytoplasmic retention (Varelas et al. 2010). Interestingly, Crumb3 is highly 
repressed in the α6Bβ1 cells (Table S2.1- complete list), indicating the 
inactivation of this polarity complex in the CSCs. In the future, it will be 
informative to examine whether restoration of crumb3 is able to ablate the TAZ 
activation in the CSCs. 
The above five factors that regulate the activation of TAZ and YAP require 
LATS1/2 in the canonical hippo pathway (Moroishi et al. 2015). Interestingly, I 
found that knockdown of LATS1/2 in the non-CSC population, which expresses 
α6Aβ1, did not promote the activation of TAZ as assessed by expression of TAZ 
target genes (Fig 2.3M). Nevertheless, it does not negates the involvement of  
hippo pathway in TAZ regulation in my system. First, limited efficiency of LATS2 
knockdown (Fig 2.3M) may still retain the function of LATS2 so that TAZ remains 
inactivated in α6A cells. Also, I observed more LMα5 induction by transfection of 
a LATS-insensitive TAZ, than by transfection of a wild type TAZ in α6A cells 
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(data not shown). Further experiments that involve 1) a more detailed 
examination on the effects of hippo components on TAZ activity in the α6A cells 
and 2) the re-activation of the hippo pathway in the CSC population that 
expresses α6B will clarify this question. 
Non-canonical TAZ/YAP activation: My results suggest that activation of TAZ by 
α6Bβ1-LM511 involves non-canonical hippo pathways. Non-canonical activation 
of TAZ and YAP is mediated by factors that directly regulate the activity of TAZ 
and YAP (Piccolo et al. 2014). The known factors that belong to this category 
include mechanotransduction (Aragona et al. 2013) and the Wnt pathway 
(Azzolin et al. 2012). Mechanical force has been reported as an independent 
factor to activate YAP and TAZ and a distinct mediator for contact inhibition 
(Aragona et al. 2013). It has been shown that cells on stiff substrates exhibit 
much higher activation of YAP and TAZ than cells on soft substrates (Dupont et 
al. 2011). Also, the extent of cell stretching, which is affected by the available 
surface area, positively affects the activation of YAP and TAZ (Aragona et al. 
2013). These effects of mechanical tension are mediated by the availability of the 
F-actin polymerization and stress fibers inside the cell (Dupont et al. 2011; 
Aragona et al. 2013). Interestingly, these effects on YAP and TAZ activation by 
mechanical tension are independent of regulation by the canonical hippo 
pathway, GPCR, and the Wnt pathway (Aragona et al. 2013). Factors that 
generate or contain stress fibers, including Rho GTPases and F-actin-
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capping/severing proteins, respectively, control the mechanotransduction-
mediated YAP and TAZ activation (Dupont et al. 2011; Aragona et al. 2013). My 
current study implicates the involvement of mechanotransduction in TAZ 
activation. As stated in the Introduction, integrins are key receptors that affect 
cytoskeleton by Rho GTPase (Srichai and Zent 2010), which regulates stress 
fibers, through the formation of the FA complex (Srichai and Zent 2010). Indeed, 
I observed that α6Bβ1 cells have more stress fibers than α6Aβ1 cells when 
plated on laminin (Fig 4.1). In 
accordance with the data, my 
RNA-seq data revealed that 
the α6Bβ1 cells express less 
F-actin-capping/severing 
proteins (e.g. cofilin1) than do 
the α6Aβ1 cells (Table S2.1- 
complete list). Moreover, the α6Bβ1 cells 
generate 3-fold higher tension on laminin 
than the α6Aβ1 cells (data not shown). 
Furthermore, α6Bβ1 cells express higher 
levels of PKC-ε (Fig 4.2), a specific type of 
PKC that has been reported to transduce shear stress via Erk1/2 activation 
(Traub et al. 1997) . These data, which are not included in my paper, are 
Fig 4.1 
Fig 4.2 
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important initial data for further examination of the involvement of LM511/α6Bβ1 
in mechanotransduction, and subsequent regulation of TAZ and YAP.  
The Wnt pathway can impact TAZ and YAP activation (Azzolin et al. 2012; 
Azzolin et al. 2014). The Wnt pathway is mediated by the regulation of the 
transcription factor β-catenin. In the absence of Wnt signals, β-catenin 
complexes with GSK3, APC, Axin and β-TRCP (Clevers 2006). This complex 
activates the E3-ligase β-TRCP and promotes proteasomal degradation of β-
catenin (Clevers 2006). When Wnt ligands bind to the surface co-receptors 
Frizzled/LRP, they trigger the dissociation of the complex and induce nuclear 
translocation of β-catenin that activates Wnt target genes (Clevers 2006). 
Importantly, YAP and TAZ have been found to be constitutively associated with 
the aforementioned inhibitory complex of β-catenin, and they are required for 
recruitment of β-TRCP to this inhibitory complex (Azzolin et al. 2012; Azzolin et al. 
2014). Thus, loss of cytoplasmic YAP and TAZ promotes β-catenin stability and 
nuclear translocation (Azzolin et al. 2012; Azzolin et al. 2014). Moreover, the 
involvement of TAZ and YAP in this complex is not only responsible for their 
degradation, but also required for their cytoplasmic retention (Azzolin et al. 2012; 
Azzolin et al. 2014). In another words, activation of the Wnt pathway also 
activates YAP/TAZ, and vice versa (Piccolo et al. 2014). In accordance with this 
mechanism, I found that several Wnt target genes (Nusse 1997-2014), including 
cyclin D1, DKK1, and WISP, are upregulated in the α6Bβ1 cells (Table S2.1- 
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complete list), suggesting the activation of the Wnt pathway by the α6Bβ1 
signaling. Thus, further investigation should examine the involvement of the Wnt 
pathway in LM511-α6Bβ1 signaling.  
Target genes of TAZ: The known gene targets of TAZ remain very limited, 
primarily because of the inability of TAZ to bind DNA directly. Nevertheless, 
some classical TAZ-specific genes have been identified, including CTGF, CYR61, 
and ANKRD1 (Aragona et al. 2013). Several of these genes are also targets of 
YAP. One exceptional finding in my study is that LMα5 is a TAZ target gene, and 
it is not affected by YAP. Moreover, I also observed that TAZ can also potentially 
downregulate components of LM332, LMγ2 (Table S2.1). Interestingly, this 
observation has been corroborated by a recent study on TAZ target genes, which 
suggests that TAZ can suppress LMα3, LMβ3, and LMγ2 (Frangou et al. 2014). 
Taken together, my study has unveiled a potential set of laminin genes that are 
specifically regulated by TAZ. 
Function of TAZ in breast CSCs: It has been shown that TAZ is both essential 
and sufficient for breast CSCs. However, concrete mechanisms for how TAZ 
regulates breast CSCs remain elusive. Here, my study has revealed that TAZ 
promotes the CSC niche, composed of LM511, and LM511, in turn, drives TAZ 
activation and CSC properties via α6Bβ1. This positive feedback signaling 
mediated by TAZ serves as an important mechanism for sustaining breast CSCs. 
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Also, TAZ is involved in remodeling the ECM meshwork of CSCs. Specifically, 
TAZ activation potentially represses the non-CSC laminin, LM332 (as discussed 
before). Moreover, TAZ activation also induces the CCN proteins, CTGF and 
CYR61 (Piccolo et al. 2014). These proteins are also ligands of α6β1 in the ECM 
(Chen et al. 2001), and they mediate endothelial cell adhesion and migration 
(Chen et al. 2001). Thus, it is conceivable that TAZ activation has an impact on 
the ECM that make it gain both CSC-maintaining and angiogenic properties. 
Further work should focus on elucidating 1) the specific TFs that cooperate with 
TAZ and 2) mechanisms of TAZ-mediated gene activation and repression. These 
investigations will expand our understanding in TAZ-specific target genes and 
TAZ-mediated functions in breast CSCs. 
Other signaling pathways regulated by LM511: Apart from TAZ, it has been 
reported that LM511-integrin signaling can also regulate the sonic hedge hog 
pathway (Shh) and PI3K signaling (Spenle et al. 2013). The sonic hedgehog 
pathway is known to maintain stemness (Goel et al. 2013). My study also 
potentially link the LM511/α6Bβ1 signaling to the Shh pathway, because Gli2, a 
key transcription factor of the Shh, is a target gene of TAZ (Zhao et al. 2010) and 
it is also upregulated in the α6Bβ1 cells (Table S2.1 – complete list). Gli2 can 
bind to the promoters of Gli1 and Shh and further amplify the Shh pathway and 
induce stem cell maintenance subsequently (Eichberger et al. 2008; Goel et al. 
2013).  
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A link between LM511 and the Shh pathway is based on the analysis of 
the LMα5 knockout mice (Spenle et al. 2013). In these mice with LMα5 deletion 
in the skin, GLi1 and Shh are repressed, and the hair follicles are defective 
(Spenle et al. 2013). This defective phenotype could be rescued by exogenous 
expression the Shh transgene, indicating the Shh pathway is downstream of 
LM511-mediated signaling (Spenle et al. 2013). Conditional knockout of the 
LMα5 in the dental epithelium also resulted in the reduction of the Shh mRNA 
(Spenle et al. 2013). Moreover, the lung specific LMα5-null mice showed similar 
defects to the mice with lung specific Gli2 knockout (Spenle et al. 2013). 
Although these data implicated the role of LM511 signaling in regulating the Shh 
pathway, they do not provide direct evidence. The “LM511/α6Bβ1TAZ” axis 
described in my study provides a potential mechanism for a causal relationship 
between LMα5 and the Shh pathway. Thus, it will be interesting to see whether 
LM511 activates the Shh pathway by TAZ-mediated Gli2 transactivation. 
Cell adhesion studies have also established a link between PI3K and 
LM511, as a classical integrin outside-in signaling as described in the 
Introduction. It has been shown that dental epithelial cells cannot spread on a 
LM511 matrix in the presence of wortmanin, a PI3K inhibitor (Spenle et al. 2013). 
Another study showed that the anti-apoptotic effects triggered by the cells 
adhesion on LM511/521 are ablated by wortmanin or dominant negative Akt 
Chapter IV                 127 
 
(Spenle et al. 2013). These functional studies clearly showed a causal link 
between LM511-integrin ligation and PI3K activation. 
 
Integrin Splicing 
At least three α integrin (α3, α6 and α7) subunits have alternative splicing that 
generate A and B forms that differ only in their cytoplasmic domains (DiPersio et 
al. 2001). My study has revealed distinct roles of α6A and α6B splice variants in 
regulating CSCs by affecting TAZ activity. Although both α6A and α6B have the 
same extracellular sequence, my data indicated that α6B is a functionally 
preferred ligand, rather than a biochemically preferred ligand to LM511, since I 
observed that cells that express α6A adhere 50% less to LM511 than cells that 
express α6B (Fig 2.1C). Another data supporting this notion is that cells with α6B 
splice variant knockout have a compensatory elevation of α6A splice variant 
(Goel et al. 2014), but these cells are unable to mediate the adhesion on the 
LM511 matrix, further proving that α6A cannot transmit the same adhesive signal 
to cells as does α6B on LM511 (Fig 2.1D). My data also indicated that β4 integrin 
subunit is dispensible for α6B mediated signaling, because SUM1315 cells 
engineered to express α6B can induce TAZ activation in the absence of β4 
expression (Fig 2.3B, F). These data confirmed that α6Bβ1 is the functional 
integrin heterodimer. An immediate question is how the two splice variants 
Chapter IV                 128 
 
function differentially on LM511, providing that α6A and α6B have the same 
extracellular sequences? One possible mechanism is that α6A and α6B harbor 
different PDZ binding motifs at their C-terminus, which transmit differential 
intracellular signals. α6A has a classical PDZ binding motif, TSDA, in contrast, 
α6B harbors a non-classical PDZ binding motif, ESYS (Tani and Mercurio 2001). 
It has been shown that both these PDZ motifs are critical to mediate the 
interactions between the α6 splice variants with GIPC-1 (also called TIP-2), a 
major PDZ domain-containing protein that interact with the PDZ motifs of the α6 
splice variants (Tani and Mercurio 2001; El Mourabit et al. 2002).  It is possible 
that the non-classical PDZ motif, ESYS, could regulate the function of GIPC-1 in 
a way that is different from α6A by promoting a distinct conformation change, or 
compete with the binding of α6A to GIPC-1. Thus, potential differential 
downstream signals triggered by α6A-GIPC-1 and α6B-GIPC-1 could lead to 
different, even opposite signaling consequences. In the future, swapping the PDZ 
motifs between α6A and α6B or crystallography of the ESYS-GIPC will clarify the 
above mentioned hypothesis.  
 The link between PDZ motifs of α6 splice variants and GIPC-1 also 
implicates potential mechanism of differential regulation of TAZ activity by α6 
splice variants. GIPC-1 can bind to RGS19, an inhibitory protein for α subunit of 
GPCRs (Gα) (Katoh 2013). Dimerization of GIPC-1 leads to the clustering of Gα 
to RGS19 and thus attenuating Gα signaling (Katoh 2013). Interestingly, it is 
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known that the majority of the Gα subunits are able to activate TAZ and YAP (Yu 
et al. 2012a). These pieces of information provide the following hypothesis of 
how α6 splice variants regulate differential TAZ/YAP functions: α6A-GIPC-1 
association induces the dimerization of GIPC-1 and inhibit the Gα subunits by 
RGS19, thus, the activity of TAZ is contained by lack of GPCR signaling. In 
contrast, α6B may compete with α6A to bind GIPC-1 and the α6B-GIPC-1 
complex dissociates the GIPC-1 dimers and thus it releases RGS19 and 
promotes GPCR signaling, which further activates TAZ. Biochemical assays that 
examine the dimerization status of GIPC-1, interaction of RGS19-GIPC-1, and 
interaction of RGS19- Gα subunits in cells express either type of α6 splice 
variants will test this hypothesis.  
 Moreover, the PDZ motifs residing in the α6 splice variants can also 
potential bind other polarity proteins, including Scribble and PALS1. Scribble has 
4 different PDZ domains (Ren et al. 2015), thus it can potentially serve as a 
scaffold protein to assemble several protein subunits that have PDZ motifs. It is 
known that TAZ interacts with Scribble, possibly through the PDZ motifs in the C-
terminal of TAZ (Cordenonsi et al. 2011). It is possible that α6A is associating 
with the TAZ/Scribble complex thus it inhibits the function of TAZ by sequestering 
it on the membrane and inactivating it via recruiting the LATS complex. In 
contrast, α6B, harboring a different PDZ motif, may interact with Scribble and 
disrupt the TAZ/Scribble/LATS complex. Another possibility is that the PDZ motif 
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of α6B can associate with PALS1, a key component of the polarity complex, 
crumb, thus inhibiting the crumb-PALS1 association by steric hindrance of the 
PDZ domain (Ivanova et al. 2015). Although these hypothesis are based majorly 
on the PDZ motifs, the facts that PDZ motifs of the α6 splice variants are highly 
conserved across species and they can function independently in chimeric 
proteins (El Mourabit et al. 2002) lay support to their potentials in mediating 
differential TAZ activation. Interestingly, my side-data implicates that α6A, but not 
α6B, maintain cellular polarity, because when α6Aβ1 cells and α6Bβ1 cells are 
plated on LM111, α6Aβ1 cells form polarized cobblestone structures, while 
α6Bβ1 cells are depolarized (Fig 4.1). Future experiments, with a focus in 
biochemical characterization of the PDZ motifs of the α6 splice variants, will 
highly expand our knowledge on the mechanism that dictates the distinct 
functions exerted by α6B and α6A. 
Sequence alignment of the α3B and α6B showed a significant 
conservation (60%) on the AA sequences of their cytoplasmic sequences 
(DiPersio et al. 2001). This high conservation suggests a common pathway of the 
evolution of their cytoplasmic AA sequences, splicing mechanisms and function. 
Thus, the functional differences between α6A and α6B may be able to shed 
some light on distinct roles of the α3B and α3A integrin. In support of this idea, a 
comparative study on the difference between α3A and α3B revealed that when 
cells lack the ligand for α3β1 integrin, α3A localizes at the cell-cell contacts, while 
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α3B localizes intracellularly (DiPersio et al. 2001). This observation implicates 
that α3A is more involved in the maintenance of the basolateral polarity of cells 
than α3B – a situation similar to α6A and α6B.  
On one hand, considering the similarity in the sequence and splicing 
mechanism between α6B and α3B, future work on elucidating the functional 
mechanism of the cytoplasmic domain of α6B may also give hints to α3B function. 
For example, it will be interesting to explore whether the splicing of α3 is also 
important for generating breast CSCs and whether α3A and α3B responds 
differentially when engages LM511.  
On the other hand, however, α3 splice variants do not have PDZ motif in 
their C-terminus, nor do they associate with GIPC-1, suggesting a major 
functional difference between α3 and α6 integrins. Because α3β1 can also 
mediate the cell adhesion on LM511 (Chia et al. 2007), the contribution of α3β1 
integrin in breast CSCs is worth being investigated in the future. 
 
Regulation of β4 Transcription 
My research on the β4 transcription has benefited from the ENCODE project that 
provided important functional and sequence insights on the β4 gene (Consortium 
2012). First, the DNAase mapping on the β4 gene showed a DNAse-
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hypersensitive region from -830+999 (relative to transcription start site, TSS) 
(GEO accession: GSE30567)1. It is known that hypersensitive regions in the 
gene promoters correlate with active regulatory regions in the genome, because 
they are not associated with repressive protein complexes and thus they are 
accessible to DNAse and transcription factors (Sabo et al. 2006). Second, I found 
three highly conserved genomic regions within the DNAse hypersensitive region 
of β4 (Kent et al. 2002). These regions are conserved across several species, 
suggesting their functional importance in regulating β4 (Kent et al. 2002). The 
first region contains a TATA-like box, “ATAAA”, and a GC-rich sequence, which 
is probably involved in the transcription initiation, because TATA box and Sp1 
(the TF that binds GC-rich sequence) have been shown to stimulate transcription 
(Mitchell et al. 1986). The second is the Ap-1 binding site, “TGA(C/G)TCA”, 
which potentially recruits the activator protein 1 (Ap-1) (Chinenov and Kerppola 
2001). The third locus contains the E-box/ Snai1-binding sequence, “ACAGGTG”, 
which can recruit various TFs ranging from basic-helix-loop-helix family members 
to Snail family members (Snai1 and Slug). 
Previous studies have linked β4 transcription with the growth factor 
signaling mediated transcription activator, Ap-1. Ap-1 is a heterodimer between 
Fos family (c-fos, Fra1 and Fra2, FosB) and Jun family (c-jun, JunB, JunD) TFs 
or a homodimer of Jun family TFs (Chinenov and Kerppola 2001). These Ap-1 
TFs can be activated by MAPKs (Hazzalin and Mahadevan 2002). Biochemical 
1 This data is from the UW ENCODE group. 
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studies using keratinocytes have shown that Ap-1 factors including Fra1, Fra2, 
JunB and JunD can potentially bind the promoter of β4 on its Ap-1 binding site, 
and promote β4 transcription (Takaoka et al. 1998; Oldak et al. 2010).  
My study has revealed that EMT represses β4 via Snai1 through its 
binding to the third conserved locus that contains the E-box (CANNTG) 
“CAGGTG” (Chang et al. 2013). Although the β4 promoter contains several other 
E-box sequences, which are very similar to the Snai1-binding site, I found that 
Snai1 does not associate with them, consistent with their low conservation 
across species (Chang et al. 2013). As such, additional factors may cooperate 
with Snai1 and stabilize its binding. Based on analysis by JASPAR, a powerful 
online tool for prediction of TF binding (Mathelier et al. 2014), Sox9, E2F1, and 
E2F4 are potential TFs that bind loci that are adjacent to the E-box/Snai1-binding 
sequence within the third conserved region. Interestingly, our lab has shown 
previously that E2F1-3 can regulate β4 mRNA expression (Yoon et al. 2006). My 
work identified Id2 as a positive regulator of β4 through inhibiting Snai1. However, 
silencing Id2 does not affect the binding of Snai1 on the β4 promoter. Future 
work may identify novel cooperative factors to Snai1 and the mechanism 
involved.  
Another TF that I identified to activate β4 is KLF4 (not included in my 
paper). I found that KLF4 expression can rescue the repression of β4 by Snai1 
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(Fig A.1.2-A1.4). This observation suggests that KLF4 can regulate β4 
transcription by affecting Snai1 expression (Yori et al. 2011) (Fig A.1.4) or 
competing with Snai1 on the Sp-1 binding region (Shie et al. 2000). Also, it has 
been reported that p63 can regulate cell adhesion and survival program, with one 
of its trans-activation targets being β4 (Carroll et al. 2006). Although the paper 
claimed the direct binding of p63 on the β4 promoter by chromatin IP (ChIP), my 
rigorous examination on the data question this conclusion, because the study 
used a ChIP primer pair that spanned more than 1000 bps (Carroll et al. 2006). 
Rather, a recent study showed that p63 induces KLF4 in a “p63ZNF750KLF4” 
axis (Sen et al. 2012). Thus, it is possible that p63 positively regulates β4 by 
KLF4 mediated transcription activation.  
Hypoxia has been shown to upregulate β4 mRNA expression (Wilkinson 
et al. 2009). Indeed, my pilot data showed that cobalt-chloride treatment 
(mimicking hypoxia) of prostate epithelial cells induces β4 transcriptional activity 
(data not shown). Thus, it will be interesting to examine the involvement of Hif 
TFs in β4 transcription. Other TFs that may repress β4 transcription are AP-2α/2γ. 
This deduction is based on the published data from the Encode project that 
showed significant enrichments of these two transcription factors within the 
DNAase hypersensitive region of β4 in Hela cells (Consortium 2012) (GEO 
accession: GSE30567)2. Indeed, mice with double genetic knockouts of Ap-2α 
2 These data were generated and analyzed by the labs of Michael Snyder, 
Mark Gerstein and Sherman Weissman at Yale University; Peggy Farnham at 
UC Davis; and Kevin Struhl at Harvard. 
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and Ap-2γ in the skin showed a significant expansion of the β4+ cells in the 
epidermis (Wang et al. 2008).  
In summary, my work has revealed novel directions to gain a more 
comprehensive understanding of the mechanisms that control the transcription of 
integrin β4. 
 
Regulation of Snai1 Function 
Snai1 is known as an important player in breast progression (Moody et al. 2005), 
and one major mechanism for its role is that it represses key tumor suppressor 
genes: E-cadherin and PTEN (Batlle et al. 2000; Cano et al. 2000; Herranz et al. 
2008). Thus, intense research has focused on the regulation of Snai1 expression 
and function. Two mechanisms have been proposed. The first is the regulation of 
Snai1 stability and localization. The Wnt pathway player, GSK3β, can 
phosphorylate Snai1 on 6 serine residues, and this phosphorylation promotes the 
proteasomal degradation of Snai1 by β-TRCP (a protein E3-ligase) and it 
excludes Snai1 from the nucleus and inhibits its function involved in transcription 
(Zhou et al. 2004). Also, the Wnt target, Axin2, has been shown to work as a 
negative regulator of GSK3β, and it stabilizes Snai1 protein (Yook et al. 2006). 
Another E3-ligase, FBXL14, has also been shown to mediate the proteasomal 
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degradataion of Snai1 through a distinct ubiquitination site (Vinas-Castells et al. 
2010). The second mechansim involves the recruitment of transcriptional co-
repressors, which induce the repressive histone modifications on the target 
genes by Snai1. These co-repressors are required for the function of Snai1. 
Specifically, Snai1 has been shown to recruit components of the polycomb 
complex 2 (PRC2), Suz12 and Ezh2. The recruitment of the PRC2 induces the 
trimethylation on the H3K27 (H3K27Me3) and subsequent gene repression 
(Herranz et al. 2008). HDAC1 and HDAC2, which are factors that mediate 
histone deacetylation, are also recruited by Snai1 (Peinado et al. 2004). The third 
class of co-repressors recruited by Snai1 is the LSD1/Corest complex (Lin et al. 
2010a; Lin et al. 2010b). This complex induces the demethylation on the 
H3K4Me and H3K4Me2, which are prerequisites for the transcription activation 
marker, H3K4Me3. The fourth class of Snai1-associated co-repressors is 
responsible for establishing another histone repressive marker, methylation on 
the H3K9. These factors are Suv39H1 and G9A, which mediate the H3K9Me3 
and H3K9Me2, respectively (Dong et al. 2012a; Dong et al. 2012b). Importantly, 
the majority (Suz12, HDAC1/2, LSD1/Corest, Suv39H1) of the aforementioned 
co-repressors require an intact SNAG domain of Snai1 to interact with Snai1. My 
study identified Id2 as a novel inhibitor of SNAG domain binding. Thus, it 
potentially inhibits the binding of most of co-repressors mentioned above. 
Moreover, this mechanism is distinct, because it indicates that Id2 directly inhibits 
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DNA-bound Snai1. However, I also observed that overexpression of Id2 alone is 
not sufficient to reverse the repressive effect by Snai1, suggesting additional 
factors are required. Interestingly, in another study that also showed that DNA-
bound Snai1 does not repress target genes in epithelial cells, researchers found 
that protein kinase D1 (PDK1) mediated phosphorylation of Snai1 is required for 
the inhibition of the function of DNA-bound Snai1 (Bastea et al. 2012). Future 
work should further explore the relationship between PDK1, Id2 and other factors 
in inhibiting the function of DNA-bound Snai1. 
 
The role of β4 in Breast Cancer Progression 
The two studies in my thesis have indicated that 1) β4 is repressed during the 
EMT, and 2) breast CSCs do not express β4 integrin subunit. These results are 
consistent with the existing literature, which showed the EMT of the breast 
cancer cells generates CSC properties (Mani et al. 2008; Scheel et al. 2011). 
Moreover, it has been shown that exogenous β4 expression inhibits the factors 
(TGF-β1 and LIF) that maintain the CSCs (Domogatskaya et al. 2008; Gal et al. 
2008; Chen et al. 2009). Given that β4 has been implicated in breast tumor 
formation, an important question is whether β4 impacts the function of CSCs?  
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One possibility is that it supports the CSC through paracrine signaling 
from β4+ non-CSCs. It has been shown that β4 can induce NF-κB activation 
through activation of the Rho GTPase Rac1 (Zahir et al. 2003). Because 
inflammation has been linked to the generation of CSCs because of its 
involvement in the EMT (Cabarcas et al. 2011), β4+ non-CSCs are potentially 
creating a proper inflammatory microenvironment for CSCs. Moreover, our lab 
has reported that β4 can stimulate VEGF secretion by the activation of the PI3K, 
which leads to the increased translation of VEGF mRNA (Chung et al. 2002). The 
amplified VEGF signaling by β4 in the non-CSCs can promote CSC function 
because that 1) VEGF signaling is important for the nuclear translocation of the 
EMT inducer Snai1 (Mak et al. 2010), and 2) maintenance of the CSC population 
depends on VEGF through Nrp2 (a VEGF receptor) activation (Goel et al. 2012). 
Nrp2 mediates the repression of the splicing factor ESRP1, the loss of which 
triggers the expression of the CSC-associated α6B splice variant (Goel et al. 
2014). Thus, the existence of β4+ non-CSCs can potentially provide important 
paracrine signals to the CSCs and promote CSCs in a non-cell autonomous 
manner. It will be important to characterize the β4+ population in more detail and 
evaluate its function. 
Another possibility is that β4 directly affects the survival, migration and 
proliferation of non-CSCs. Our lab has showed that the α6B enriched CSC 
population is not stable and it spontaneously gives rise to non-CSCs, which are 
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β4 positive (Goel et al. 2014). It has been shown that non-CSCs grow much 
faster than the CSCs and they are contributing to the majority of the mass of a 
tumor (Jordan et al. 2006). Moreover, the maintenance of non-CSCs is also 
important for tumor progression (Jordan et al. 2006; Polyak 2007; Visvader and 
Lindeman 2008). Although the CSC population has several mechanisms for 
survival, including Snai1 and TAZ mediated upregulation of the BCL2 survival 
family members, Bcl-Xl and Survivin, respectively (Vega et al. 2004; Cordenonsi 
et al. 2011), the non-CSCs may require other mechanisms to survive. One of the 
the survival factor for non-CSCs could be β4 integrin. β4 integrin can promote 
cell survival by PI3K activation or NF-κB activation after it ligates with its ligands 
LM332 (Zahir et al. 2003). Indeed, LM332 has been shown to be upregulated in 
primary breast carcinoma (Miyazaki 2006). Moreover, β4 can remodel the ECM 
and affect cell behaviors. β4 has been shown to exert traction forces on the BM 
and concentrate laminin substrates toward the tumor cells (Rabinovitz et al. 
2001). This effect by β4 promotes integrin signalings in the non-CSCs. Also, it 
has been shown that β4 stimulates expression of matrix proteinases MT-MMP1 
and BMP-1 (Chen et al. 2009). Both of these factors are able to cleave the 
laminin γ2 chain of the LM332 and turn it into the active form that stimulates cell 
migration (Amano et al. 2000; Veitch et al. 2003; Miyazaki 2006). Thus, the 
migration of the non-CSCs cells can be stimulated by β4. Also, β4 can promote 
cell proliferation by inducing EGFR ligands: S100A4 and the cleaved product of 
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Conclusion Remarks and Perspectives 
My thesis work provides novel and significant insights into the function and 
regulation of the α6 integrins. This work impacts our understanding of integrin 
biology, mammary epithelial biology and breast cancer.  
In the first project, I discovered a major role for a specific ECM protein 
complex, LM511, as a matrix niche for CSCs, and demonstrated that it is the 
preferred ligand for the α6Bβ1 integrin splice variant. LM511/α6Bβ1 signaling 
maintains the function of CSCs and it promotes tumor initiation. Consistent with 
this finding, I observed that cancer cells with high surface-bound LMα5 isolated 
from breast tumors exhibit CSC properties. Future studies should continue to 
explore the usefulness of LMα5 as a marker for breast CSCs and investigate why 
this specific laminin engages α6Bβ1 and promotes CSC functions.  
My work also provides a mechanism for how LM511/α6Bβ1 signaling 
promotes the function of breast CSCs, by activating the Hippo transducer TAZ. 
Although TAZ has been studied extensively in cancer, little was known about 
how it impacts the function of CSCs. My demonstration that TAZ regulates the 
formation of a LM511 matrix provides one such mechanism. Elucidating how 
LM511/α6Bβ1 signaling activates TAZ is a critical area for further investigation.   
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A major goal in breast cancer research is to identify specific therapeutic 
targets for CSCs. My thesis work suggests that inhibitors of the LM511/α6Bβ1 
interaction or the splicing program that generates α6B could be effective in 
inhibiting breast CSCs.  
My second project has identified a novel mechanism that regulates β4 
expression, which involves Snai1-mediated epigenetic repression of β4 by the 
PRC2-associated histone mark, H3K27Me3. Although a number of co-repressors 
of Snai1 have been identified that are essential for its epigenetic function, few 
transcriptional antagonists of Snai1 were known. My study identified Id2 as such 
an antagonist that functions to inhibit binding to the SNAG domain of Snai1, 
which interacts with co-repressors. Also, the Id2-Snai1 interaction provides a 
mechanism for the reversible and dynamic regulation of β4 in breast cancer. This 
mechanism ensures the proper control of β4 by cycles of “EMT-MET-EMT”, which 
are proposed to be occurring during the cancer progression (Hanahan and 
Weinberg 2011). Future work on identifying other epigenetic regulators of β4 is 
envisioned.  
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Appendix 
The attached are unpublished projects. 
Project 1: Klf4 Regulates β4 Transcription 
Rationale:  
The data in the third chapter has identified Snai1 as a strong repressor of β4 
transcription. However, specific transcription activator of β4 is still largely 
unknown. This study aimed to identify novel transcription activators of β4, using 
the same cell system that was used in chapter III. I found 3 potential transcription 
activators (Nfe2l2, Klf4, and ZNF704) of β4 based on these criteria: 1) they are 
upregulated in the epithelial cells compared to the mesenchymal cells; 2) their 
transcription binding site are found in the β4 promoter or they are potential 
regulators of Snai1. I cloned these transcription factors and expressed each of 
them in the NMuMG cells with stable Snai1 expression. The factors that can 
rescue the Snai1-mediated repression of β4 are strong activators of β4.  
Results: 
The infection efficiency of viruses that encode Nfe2l2, Klf4 and ZNF704 are 
about similar (~80%) (Fig A.1.1). Among these factors, I found only Klf4 can 
rescue the β4 repression by Snai1, as indicated by mRNA (Fig A.1.2) and protein 
expression (Fig A.1.3), and itself is also sufficient to induce the expression of β4 
in the parental NMuMG cells (Fig A.1.4). A closer look on the Snai1 expression 
by Klf4 has revealed that Klf4 can repress Snai1 expression (Fig A.1.3, A.1.4), 
and this repression may relate to the protein stability of Snai1 (Fig A.1.4), 
because I found that the ectopically expressed Snai1 can also be reduced by 
Klf4 expression. A final proof of the positive regulation of β4 by Klf4 is that 
overexpression of the mouse Klf4 protein in a β4-negative human breast cancer 
cell line is able to induce de novo β4 expression (Fig A.1.5).  
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Project 2: Zeb1 Regulates the DNA Methylation  
Rationale: 
The data in the third chapter has identified that Snai1 mediates the establishment 
of the repressive marker, H3K27Me3, on the β4 promoter. However, little is 
known what factor mediates the DNA methylation on the β4 promoter. It is known 
that Snai1 can induce the expression of Zeb1, which is another EMT inducer. In 
contrast to Snai1, which is induced during EMT and suppressed during MET, the 
expression of Zeb1 increases during EMT and does not change significantly 
during MET. Importantly, changes in the DNA methylation status of β4 promoter 
show the same pattern as does Zeb1. To this end, this study examines the 
hypothesis that Zeb1 mediates the DNA methylation of β4 promoter in the same 
system as in chapter III. 
Results: 
The current study discovered an unexpected role of Zeb1 in mediating the DNA 
methylation of the β4 promoter and potentially other Zeb1 target genes. 
Particularly, I found that overexpression of Snai1 can induce the expression of 
Zeb1 (Fig A.2.1), and de novo DNA methylation on the β4 promoter (Fig A.2.2). 
These effects by Snai1 mimic the situation during an EMT (Fig A.2.3). 
Importantly, I found that Snai1 induced de novo DNA methylation is blunted by 
loss of Zeb1 (Fig A.2.4, A.2.5). Although the data is complexed by the fact that 
overexpression of the shRNA vectors that encode shGFP and shZebs alone can 
induce DNA demethylation on the β4 promoter (Fig A.2.4, A.2.6, see shGFP 
cells), the relative fold changes of the DNA methylation of the β4 promoter within 
each experiment/control group leads to the conclusion that loss of Zeb1 render 
the β4 promoter resistant to Snai1-mediated de novo DNA methylation (Fig 
A.2.4- A.2.8). The methylation effect by Zeb1 has to cooperate with the function 
of Snai1, because overexpression of Zeb1 alone does not increase the DNA 
methylation of the β4 promoter (Fig A.2.9, A.2.10).  
Using another system, which is the EPTH/MES human system used in 
chapter II, I tried to correlate the function of Zeb1 with DNA methylation, because 
EPTH and MES cells express different levels of Zeb1 mRNA (Fig A.2.12). 
However, although β4 is expressed differentially in EPTH and MES cells, my 
analysis on its promoter indicates its expression is not controlled by DNA 
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methylation, because β4 promoter is unmethylated in both cells (data not shown). 
As a result, I examined another Zeb1 target, Mir200c, and found that its promoter 
is highly DNA methylated in the MES cells and unmethylated in the EPTH cells 
(Fig A.2.11). In order to assess the function of Zeb1 on DNA methylation of 
Mir200c, I partially knocked down Zeb1 (<50%) by SiRNA in the MES cells (Fig 
A.2.13). Interestingly, I observed a mild decrease in the DNA methylation of the 
Mir200c promoter, from 73% to 68%, upon loss of Zeb1 (Fig A.2.14). Future 
experiments should be carried out to confirm this result by establishing a stable 
Zeb1 knockdown with at least 80% efficiency in the protein expression. In 
summary, these results have implicated a role of Zeb1 in maintaining DNA 
methylation. Whether this is a global event by Zeb1 and the mechanism that how 
Zeb1 affects the DNA methylation need to be examined in further investigations. 
 
 
 
 
 
 
 
 
 
 
Appendix                 171 
 
Figures.   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
A.2.1 
A.2.2 
A.2.3 




